

# ARTHRITIS & RHEUMATISM

---

OFFICIAL JOURNAL OF THE AMERICAN RHEUMATISM ASSOCIATION  
SECTION OF THE ARTHRITIS FOUNDATION

---

## CONTENTS VOLUME 20, 1977

VOL. 20	JANUARY-FEBRUARY	No. 1
The National Arthritis Plan: An Overview <i>Ephraim P. Engleman</i> .....		1
Lyme Arthritis: An Epidemic of Oligoarticular Arthritis in Children and Adults in Three Connecticut Communities <i>Allen C. Steere, Stephen E. Malawista, David R. Syndman, Robert E. Shope, Warren A. Andiman, Martin R. Ross, and Francis M. Steele</i> .....		7
Systemic Lupus Erythematosus Associated with Klinefelter's Syndrome <i>R. Stern, J. Fishman, H. Brusman, and H. G. Kunkel</i> .....		18
Avidity of Antibodies in SLE: Relation to Severity of Renal Involvement <i>Shalom A. Leon, Anthony Green, George E. Ehrlich, Marcia Poland, and Bernard Shapiro</i> .....		23
Stimulatory Effect of Metoclopramide on the Esophagus and Lower Esophageal Sphincter of Patients with PSS <i>Manuel Ramirez-Mata, Graciela Ibañez, and Donato Alarcon-Segovia</i> .....		30
Progressive Systemic Sclerosis in a Family: Case Report of a Mother and Son and Review of the Literature <i>Robert G. Gray and Roy D. Altman</i> .....		35
Evidence of Rheumatoid Arthritis in Ancient India <i>R. D. Sturrock, J. N. Sharma, and W. W. Buchanan</i> .....		42
Resources for the Care of Arthritics in a Nonmetropolitan Community: Redding, California <i>Edward Yelin, Curtis Henke, and Wallace V. Epstein</i> .....		45
Effect of Sodium Salicylate on Human and Mouse Granulopoiesis in Vitro <i>J. D. Gabourel, M. A. S. Moore, G. C. Bagby, Jr., and G. H. Davies</i> .....		59
Effect of Altered Lymphocyte Function on Immunologic Disorders in NZB/NZW Mice. I. Favorable Response to L-Asparaginase <i>Jagdish Mehta, Linda L. Knotts, and Bevra H. Hahn</i> .....		65
Glucocorticosteroid Inhibition of Nonphagocytic Discharge of Lysosomal Enzymes from Human Neutrophils <i>Louis J. Ignarro</i> .....		73
Lactoferrin and Lysozyme Levels in Synovial Fluid: Differential Indices of Articular Inflammation and Degradation <i>Robert M. Bennett and John L. Skosey</i> .....		84
Relapsing Polychondritis: An Ultrastructural Study <i>Ken Hashimoto, Charles R. Arkin, and Andrew H. Kang</i> .....		91
Reiter's Syndrome Following <i>Shigella flexneri</i> 2a: A Sequel to Traveler's Diarrhea <i>Armin E. Good and Jane S. Schultz</i> .....		100

Proceedings of the 41st Annual Scientific Session of the American Rheumatism Association: Abstracts of Papers Presented .....	105
Editorial .....	141
Letter .....	142
ARA Announcements .....	144

VOL. 20

MARCH

No. 2 (SUPPLEMENT)

Proceedings of the Conference on the Rheumatic Diseases of Childhood .....	145-636
--	---------

VOL. 20

MARCH

No. 2

Pathways of Complement Activation in Chronic Discoid Lupus: Serologic and Immunofluorescence Studies <i>Mark A. Schrager and Naomi F. Rothfield</i> .....	637
Correlation Between Levels of Breakdown Products of C3, C4, and Properdin Factor B in Synovial Fluids from Patients with Rheumatoid Arthritis <i>L. H. Perrin, U. E. Nydegger, R. H. Zubler, P. H. Lambert, and P. A. Miescher</i> .....	647
Skin Basement Membrane Immunofluorescence in Rheumatoid Arthritis: Lack of Diagnostic Correlation <i>Daniel C. DeBoer, Roland W. Moskowitz, and Beno Michel</i> .....	653
Intracellular Collagen Fibers at the Pannus-Cartilage Junction in Rheumatoid Arthritis <i>Edward D. Harris, Jr., Audrey M. Glauert, and Alan H. G. Murley</i> .....	657
D-Penicillamine in the Treatment of Rheumatoid Arthritis <i>Ian K. Tsang, Caroline A. Patterson, Howard B. Stein, Harold S. Robinson, and Denys K. Ford</i> .....	666
Activators and Inhibitors of Fibrinolysis in Rheumatoid and Nonrheumatoid Synovial Membranes: A Histochemical Study <i>Levinus B. A. Van De Putte, Vincent Noordhoek Hegt, and Titia A. Overbeek</i> .....	671
Enhancement of in Vitro Immunoglobulin Synthesis of Rheumatoid Lymphocytes by Aggregated Human Gamma Globulin <i>Kuniomi Yamasaki and Morris Ziff</i> .....	679
Azathioprine in Early Rheumatoid Arthritis: Comparison with Gold and Chloroquine <i>I. L. Dwosh, H. B. Stein, M. B. Urowitz, H. A. Smythe, T. Hunter, and M. A. Ogryzlo</i> .....	685
Comparative Study of Immunologic Methods for Demonstration of Antibodies to Soluble Nuclear Antigens: Immunofluorescence, Hemagglutination, Complement Fixation, and Immunodiffusion <i>Masashi Akizuki, Runas Powers, Jr., and Halsted R. Holman</i> .....	693
Hyaluronic Acid Production by Irradiated Human Synovial Fibroblasts <i>Michael Yaron, Ilana Yaron, Moshe Levita, and Mala Herzberg</i> .....	702

Differences in the Collagen Types Synthesized by Lapine Articular Chondrocytes in Spinner and Monolayer Culture <i>David P. Norby, Charles J. Malesud, and Leon Sokoloff</i> .....	709
Tendon Calcifications in Chondrocalcinosis: A Clinical, Radiologic, Histologic, and Crystallographic Study <i>Jean C. Gerster, Charles A. Baud, René Lagier, Iraj Boussina, and Georges H. Fallet</i> .....	717
Prostaglandin E <sub>1</sub> Treatment of NZB/NZW Mice. I. Prolonged Survival of Female Mice <i>Robert B. Zurier, Donna M. Sayadoff, Susan B. Torrey, and Naomi F. Rothfield</i> .....	723
Antiglobulins in Juvenile Rheumatoid Arthritis <i>John J. Miller, III, Lynne Olds-Arroyo, and Toru Akasaka</i> .....	729
Synovial Chondromatosis Affecting the Temporomandibular Joint: Case Report and Literature Review <i>Phillip S. Rosen, Kenneth P. H. Pritzker, Joseph Greenbaum, Richard C. Holgate, and Arnold M. Noyek</i> .....	736
Chronic Arthropathy Associated with Rubella Vaccination <i>Spotswood L. Spruance, Robert Metcalf, Charles B. Smith, Marie M. Griffiths, and John R. Ward</i> .....	741
Case Report: Spontaneous Rupture of the Liver: An Unusual Complication of SLE <i>Peter M. Levitin, Donald Sweet, Carolyn M. Brunner, Richard E. Katholi, and W. Kline Bolton</i> .....	748
The University Rheumatic Disease Clinic: Provider and Patient Perceptions of Cost <i>Curtis J. Henke, Edward H. Yelin, Mary Lee Ingbar, and Wallace V. Epstein</i> .....	751
Current Comment: Do Medical Students in the United States Learn Clinical Rheumatology? <i>Michael D. Lockshin</i> .....	759
Letters .....	761
ARA Announcements .....	764

VOL. 20

APRIL

No. 3

Multicenter Evaluation of Synovectomy in the Treatment of Rheumatoid Arthritis: Report of Results at the End of Three Years <i>Arthritis Foundation Committee on Evaluation of Synovectomy</i> .....	765
Lymphocytes Eluted from Synovial Tissue of Juvenile Rheumatoid Arthritis Patients <i>Tore G. Abrahamsen, Stig S. Froland, Jacob B. Natvig, and Jan Pahle</i> .....	772
Antibody Levels to Enteric Bacteria in Juvenile Rheumatoid Arthritis <i>Grazyna Gutowska-Grzegorzczuk and John Baum</i> .....	779
Immunohistochemical Localization of Prostaglandin E in Rheumatoid Synovial Tissues <i>Gunnar Husby, Arthur D. Bankhurst, and Ralph C. Williams, Jr.</i> .....	785
Chalky Joint Effusion: The Result of Massive Synovial Deposition of Calcium Apatite in Progressive Systemic Sclerosis <i>Kenneth D. Brandt and Phoebe R. Krey</i> .....	792
Homozygosity for HLA-B27: Impact on Rheumatic Disease Expression in Two Families <i>Frank C. Arnett, Jr., Bernice Z. Schacter, Marc C. Hochberg, Susan H. Hsu, and Wilma B. Bias</i> ...	797

Rheumatology Manpower in California: Approaches to Assessment of Quantitative Sufficiency <i>Edward H. Yelin, Curtis J. Henke, and Wallace V. Epstein</i>	805
An Immunofluorescent Method Using <i>Crithidia Luciliae</i> to Detect Antibodies to Double-Stranded DNA <i>William Crowe and Irving Kushner</i>	811
Acetylator Phenotype in Systemic Lupus Erythematosus <i>Baher Foad, Allen Litwin, Hans Zimmer, and Evelyn B. Hess</i>	815
Quantitation of Precipitating Antibodies to Certain Soluble Nuclear Antigens in SLE: Their Contribution to Hypergammaglobulinemia <i>Peter J. Maddison and Morris Reichlin</i>	819
Aseptic Necrosis Presenting as Wrist Pain in SLE <i>Jeffrey D. Urman, Micha Abeles, Alan N. Houghton, and Naomi F. Rothfield</i>	825
Increased Spontaneous Activity of Antibody-Forming Cells in the Peripheral Blood of Patients with Active SLE <i>Daniel R. Budman, E. Bruce Merchant, Alfred D. Steinberg, Bernard Dofit, M. Eric Gershwin, Elaine Lizzio, and J. Patton Reeves</i>	829
Carrageenin-Induced Arthritis. IV. Rate Changes in Cartilage Matrix Proteoglycan Synthesis <i>D. J. Carmichael, G. C. Gillard, D. A. Lowther, C. J. Handley, and V. B. Santer</i>	834
Antigen-Induced Arthritis in Mice. I. Induction of Arthritis in Various Strains of Mice <i>Dieter Brackertz, Graham F. Mitchell, and Ian R. Mackay</i>	841
Decreased Lymphocyte Reactivity to a Suboptimal Concentration of Phytohemagglutinin in Sjögren's Syndrome <i>Joseph P. Michalski and Candace McCombs</i>	851
Connective Tissue Activation. XI. Stimulation of Glycosaminoglycan and DNA Formation by a Platelet Factor <i>C. W. Castor, J. C. Ritchie, M. E. Scott, and S. L. Whitney</i>	859
Central Nervous System Involvement in SLE: Diagnostic Profile and Clinical Features <i>Peter Small, M. F. Mass, Peter F. Kohler, and Ronald J. Harbeck</i>	869
Connective Tissue Synthesis by Cultured Scleroderma Fibroblasts. II. Incorporation of <sup>3</sup> H-Glucosamine and Synthesis of Glycosaminoglycans <i>Reza I. Bashey, Jerome S. Perlish, Susan Nochumson, Ralph E. Stephens, and Raul Fleischmajer</i>	879
Chronic Polyarthritis Associated with Hypogammaglobulinemia: A Study of Two Patients <i>Arthur I. Grayzel, Robert Marcus, Richard Stern, and Robert J. Winchester</i>	887
Preliminary Criteria for the Classification of the Acute Arthritis of Primary Gout <i>Stanley L. Wallace, Harry Robinson, Alfonse T. Masi, John L. Decker, Daniel J. McCarty, and T'sai-Fan Yü</i>	895
Letters	901
Book Reviews	906
ARA Announcements	908

VOL. 20

MAY

No. 4

Comparison of Clinical Features in HLA-B27 Positive and Negative Patients with Ankylosing Spondylitis <i>Muhammad A. Khan, Irving Kushner, and William E. Braun</i>	909
--	-----

Immune Complexes and Complement Catabolism in Ankylosing Spondylitis <i>R. Gabay, R. H. Zubler, U. E. Nydegger, and P. H. Lambert</i>	913
Association of Renal Papillary Necrosis and Ankylosing Spondylitis <i>Seth H. Lourie, Susan J. Denman, and Edward T. Schroeder</i>	917
Phytomitogen-Induced, Lymphokine-Mediated Cartilage Proteoglycan Degradation <i>Jerome H. Herman, Diane S. Musgrave, and Marie V. Dennis</i>	922
Lymphocytotoxic Antibodies: HLA Antigen Associations, Disease Associations, and Family Studies <i>Donald Raum, David Glass, Nicholas A. Soter, J. Sydney Stillman, Charles B. Carpenter, and Peter H. Schur</i>	933
Effects of Antiinflammatory Agents on the Acute Response of Immune Synovitis in Rabbits <i>Marvin B. Goldlust, Lois C. Rich, and Thomas W. Harrity</i>	937
Renal Localization of Antiglobulins in Glomerulonephritis and After Renal Transplantation <i>Roger D. Rossen, Ruth H. Rickaway, Margaret A. Reisberg, Donald B. Singer, Francis X. Schloeder, Wadi N. Suki, L. Leighton Hill, and Garabed Eknoyan</i>	947
Disseminated Immune Deposits in Lupus Erythematosus <i>Jan Brentjens, Elena Ossi, Boris Albini, Marion Sepulveda, Kyoichi Kano, John Sheffer, Peter Vasilion, Edward Marine, Tadla Baliah, Hubert Jockin, and Giuseppe Andres</i>	962
Macrophage Migration Inhibitory Factor in Rheumatoid Pericarditis <i>Mario Andreis and Eric R. Hurd</i>	969
Cellular Infiltrates in Scleroderma Skin <i>R. Fleischmajer, J. S. Perlish, and J. R. T. Reeves</i>	975
Pathology of Skeletal Muscle in Mixed Connective Tissue Disease <i>R. Oxenhandler, M. Hart, L. Corman, G. Sharp, and E. Adelstein</i>	985
Papular Mucinosis with Myopathy, Arthritis, and Eosinophilia: A Histopathologic Study <i>Lawrence P. McAdam, Carl M. Pearson, William H. Pitts, Leonard Sadoff, and M. Anthony Verity</i>	989
Digital Mucinous Pseudocysts <i>John A. Goldman, Leon Goldman, Murray S. Jaffe, and Daniel F. Richfield</i>	997
Hand Flexor Tenosynovitis in Rheumatoid Arthritis: Prevalence, Distribution, and Associated Rheumatic Features <i>Robert G. Gray and Norman L. Gottlieb</i>	1003
Ecchymosis of the Lower Leg: A Sign of Hemarthrosis with Synovial Rupture <i>Armin E. Good and Rodney V. Pozderac</i>	1009
Radiologic Vignette No. 1: A Radiologically Distinctive Cause of Low Back Pain <i>William Martel</i>	1014
Current Comment: Industrial Rheumatology: Clinical Investigations into the Influence of the Pattern of Usage on the Pattern of Regional Musculoskeletal Disease <i>Nortin M. Hadler</i>	1019
Arthritis Rounds: Acute Myocardial Infarction Following Gold Sodium Thiomalate Induced Vasomotor (Nitritoid) Reaction <i>Norman L. Gottlieb and Harvey E. Brown, Jr.</i>	1026
Discussion 1: <i>John Baum</i>	1029
Discussion 2: <i>Albert L. Waldo</i>	1030



Editorial .....	1031
Letters .....	1031

VOL. 20

JUNE

No. 5

Increased Frequency of HLA-Cw3 and HLA-Dw4 in Rheumatoid Arthritis <i>Andrew J. McMichael, Takehiko Sasazuki, Hugh O. McDevitt, and Rose O. Payne</i> .....	1037
Bone Marrow Transplantation in Patients with Gold-Induced Marrow Aplasia <i>John L. Baldwin, Rainer Storb, E. Donnall Thomas, and Mart Mannik</i> .....	1043
Monocyte-Reactive Antibodies in Patients with Systemic Lupus Erythematosus <i>William P. Arend, Toby E. Emmerich, Jerrilyn C. Sturge, and Gordon A. Starkebaum</i> .....	1049
Nucleographic Studies of Axial Spondylarthritides. I. Quantitative Sacroiliac Scintigraphy in Early HLA-B27-Associated Sacroiliitis <i>Thomas C. Namey, John McIntyre, Maria Buse, and E. C. LeRoy</i> .....	1058
C-Reactive Protein in Systemic Lupus Erythematosus <i>Stephen Honig, Peter Gorevic, and Gerald Weissmann</i> .....	1065
Pulmonary Function in Scleroderma <i>Maria Guttadauria, Herman Ellman, George Emmanuel, David Kaplan, and Herbert Diamond</i> .....	1071
Brown's Syndrome: An Unusual Manifestation of Rheumatoid Arthritis <i>Paul J. Killian, Bruce McClain, and Oliver J. Lawless</i> .....	1080
Surface Ultrastructure of Rheumatoid Articular Cartilage <i>Hiroshi Kimura, Hiroomi Tateishi, and Morris Ziff</i> .....	1085
Hip Joint Restoration in Juvenile Rheumatoid Arthritis <i>Bram Bernstein, Deborah Forrester, Bernhard Singsen, Karen Koster King, Helen Kornreich, and Virgil Hanson</i> .....	1099
Cathepsin D Agglutinators in Rheumatoid Arthritis. I. Increased CDA Titers in Serum and Synovial Fluid of Patients with Seropositive RA <i>G. Artmann, K. Fehr, and A. Böni</i> .....	1105
Chronic Nondestructive Arthritis Associated with Cutaneous Polyarteritis <i>Nathan M. Smukler and H. Ralph Schumacher, Jr.</i> .....	1114
Relation Between HLA-B27 and Clinical Features in Patients with Yersinia Arthritis <i>Ossi Laitinen, Marjatta Leirisalo, and Grethe Skylv</i> .....	1121
Plant Thorn Synovitis <i>Michael Sugarman, Dennis G. Stobie, Francisco P. Quismorio, Roger Terry, and Virgil Hanson</i> ....	1125
Thoracic Duct Drainage in SLE with Cutaneous Vasculitis: A Case Report <i>Kenneth E. Nyman, Ruth Bangert, Herbert Machleder, and Harold E. Paulus</i> .....	1129
Mechanisms Underlying the Suppression of Adjuvant-Induced Arthritis by 6-Mercaptopurine <i>Yi-Han Chang</i> .....	1135
Arthritis Rounds: Pneumocystis Carinii Associated with Polyarteritis and Immunosuppressive Therapy <i>Michael W. Bungo and William P. Beetham, Jr.</i> .....	1142
Discussion: <i>John S. Sergeant</i> .....	1145
Letters .....	1147

## ARTHRITIS: A QUARTER CENTURY OF RESEARCH

Proceedings of the Conference Commemorating the 25th Anniversary, Research Fellowship Program, The Arthritis Foundation ..... S1-S1396

## VOL. 20

## JULY-AUGUST

## No. 6

Growth and Development of Rheumatology in the United States—A Bicentennial Report: Presidential Address to the American Rheumatism Association <i>Gerald P. Rodnan</i> .....	1149
T-Lymphocyte Subpopulation in Untreated SLE: Variations with Disease Activity <i>Santiago J. Rivero, Luis Llorente, Efraín Díaz-Jouanen, and Donato Alarcón-Segovia</i> .....	1169
Aspirin and Delayed Type Hypersensitivity <i>Matthew W. Duncan, Donald A. Person, Robert R. Rich, and John T. Sharp</i> .....	1174
Comparison of Two Dosage Schedules of Gold Salts in the Treatment of Rheumatoid Arthritis: Relationship of Serum Gold Levels to Therapeutic Response <i>John T. Sharp, Martin D. Lidsky, Joseph Duffy, Howard K. Thompson, Jr., Blanche D. Person, A. Fattah Masri, and Alexander A. Andrianakos</i> .....	1179
Postinjection Nonvasomotor Reactions During Chrysotherapy: Constitutional and Rheumatic Symptoms Following Injections of Gold Salts <i>James T. Halla, Joe G. Hardin, and Julius E. Linn</i> .....	1188
HLA and Recurrent Episodic Arthropathy Associated with Rubella Vaccination <i>Marie M. Griffiths, Spotswood L. Spruance, Pearay L. Ogra, George R. Thompson, and Charles W. DeWitt</i> .....	1192
Secretion of Plasminogen Activator by Rheumatoid and Nonrheumatoid Synovial Cells in Culture <i>Henry Berger, Jr., with the Technical Assistance of Patricia R. Fleming and Patricia R. Voorhees</i> ..	1198
Local and Systemic Reactions to Puncture Injuries by the Sea Urchin Spine and the Date Palm Thorn <i>Andrea Cracchiolo III and Leonard Goldberg</i> .....	1206
Idiopathic or Traumatic Olecranon Bursitis: Clinical Features and Bursal Fluid Analysis <i>Juan J. Canoso</i> .....	1213
Pathogenesis of Cervical Discovertebral Destruction in Rheumatoid Arthritis <i>William Martel</i> .....	1217
Yersinia-Related Arthritis in the Pacific Northwest <i>Denys K. Ford, Elizabeth Henderson, George E. Price, and Howard B. Stein</i> .....	1226
Collagenase at Sites of Cartilage Erosion in the Rheumatoid Joint <i>David E. Woolley, Malcolm J. Crossley, and John M. Evanson</i> .....	1231
Cathepsin D Agglutinators and Neutral Protease Agglutinators in Rheumatoid Arthritis <i>K. Fehr, G. Artmann, M. Velvart, and A. Böni</i> .....	1240
Lymphocyte Involvement in Rheumatoid Arthritis: Studies During Thoracic Duct Drainage <i>H. E. Paulus, H. I. Machleder, S. Levine, D. T. Y. Yu, and N. S. MacDonald</i> .....	1249
Therapeutic Studies in NZB/NZW F <sub>1</sub> Mice. V. Comparison of Cyclophosphamide and Chlorambucil <i>N. Lynn Gerber, Deborah Powell, and Alfred D. Steinberg</i> .....	1263

Ultrastructural Study of Avian Synovium Infected with an Arthrotropic Reovirus <i>E. R. Walker, M. H. Friedman, N. O. Olson, and P. B. De Nee</i> .....	1269
Current Comment: A Description of Rheumatology Practice <i>The American Rheumatism Association Committee on Rheumatologic Practice</i> .....	1278
Special Topic: Attributes of the Subspecialist in Internal Medicine, with Guidelines for Training <i>The American Board of Internal Medicine</i> .....	1282
Book Review .....	1286
Letters .....	1286
ARA Announcements .....	1292

VOL. 20

SEPTEMBER-OCTOBER

No. 7

Family Study of Systemic Lupus Erythematosus: Analysis of the Clinical History, Skin Immunofluorescence, and Serologic Parameters <i>Mitchell B. Lowenstein and Naomi F. Rothfield</i> .....	1293
The in Vivo Metabolism of the Third Component of Complement in Systemic Lupus Erythematosus <i>Lawrence D. Petz, Runas Powers, James R. Fries, Neil R. Cooper, and Halsted R. Holman</i> .....	1304
Discordant Distribution of IgM and IgG Antibodies to DNA and RNA in Monozygotic Twins with Systemic Lupus Erythematosus <i>Rao J. Pillarisetty, Sidney R. Block, and Norman Talal</i> .....	1314
Limited Anti-DNA Antibody Specificity in Systemic Lupus Erythematosus <i>Ronald N. Berzofsky, Carole A. Dorsch, and Mary Betty Stevens</i> .....	1320
Depressed in Vitro B-Lymphocyte Differentiation in Systemic Lupus Erythematosus <i>Arthur M. Bobrove and Patricia Miller</i> .....	1326
Experimental Radiation Synovectomy by <sup>165</sup> Dy Ferric Hydroxide Macroaggregate <i>Clement B. Sledge, Jonathan Noble, Donald J. Hnatowich, Richard Kramer, and Sonya Shortkroff</i> ...	1334
On the Nature of Rheumatoid Rice Bodies: An Immunologic, Histochemical, and Electron Microscope Study <i>Ed Berg, Randy Wainwright, Betty Barton, Holde Puchtler, and Thomas McDonald</i> .....	1343
The Activating Effect of Synovial Fluid and Washings of Synovial Membrane on Autologous Lymphocytes in Rheumatoid Arthritis <i>J. Sebök, A. Talerman, H. W. Wouters, and P. H. Lems</i> .....	1350
The Primary Plasmin Inhibitor in Rheumatoid Synovial Fluid <i>Inge Clemmensen, Renè Donde, and R. Bach Andersen</i> .....	1354
The Effect of Synovial Tissue on the Breakdown of Articular Cartilage in Organ Culture <i>Honor B. Fell and R. W. Jubb</i> .....	1359
Failure of Proteoglycans to Form Aggregates in Morphologically Normal Aged Human Hip Cartilage <i>Elaine Perricone, Marshall J. Palmoski, and Kenneth D. Brandt</i> .....	1372
Estimates of Doses of Antiinflammatory Drugs in Man by Testing for Analgesic Potency. I. 1-Isopropyl-4 Phenyl-7-Methyl-2 (1H) Quinazalone Versus Aspirin <i>T. G. Kantor, A. Streem, and E. Laska</i> .....	1381
Polyclonal Hyperviscosity Syndrome <i>Nortin M. Hadler, Don Gabriel, K. Su Chung, Patricia Teague, and Mary A. Napier</i> .....	1388



Zymosan-Induced Arthritis: A Model of Chronic Proliferative Arthritis Following Activation of the Alternative Pathway of Complement <i>E. C. Keystone, H. U. Schorlemmer, C. Pope, and A. C. Allison</i>	1396
Use of a Hapten-Carrier System in Experimental Immune Arthritis in the Rabbit <i>Henri A. Ménard and Jean-Claude Demers</i>	1402
Patellar Whiskers and Acute Calcific Quadriceps Tendinitis in a General Hospital Population <i>L. Trujeque, P. Spohn, A. Bankhurst, R. Messner, and R. Searles</i>	1409
Interaction of D-Penicillamine with Gold Salts: In Vivo Studies on Gold Chelation and In Vitro Studies on Protein Binding <i>P. Davis and D. Barraclough</i>	1413
Special Topic: Anti-Tissue Antibodies in Rheumatic Disease: Standardization and Nomenclature <i>E. M. Tan, C. Christian, H. R. Holman, M. Homma, H. G. Kunkel, M. Reichlin, G. C. Sharp, M. Ziff, and E. V. Barnett</i>	1419
Arthritis Rounds: Case Report: Fatal Gastrointestinal Hemorrhage in Mixed Connective Tissue Disease <i>Charles L. Cooke and Harry I. Lurie</i>	1421
Discussion: <i>Robert H. Persellin</i>	1426
Letters	1428
ARA Announcements	1443

## VOL. 20

## NOVEMBER-DECEMBER

## No. 8

Treatment of Rheumatoid Arthritis with Levamisole: A Controlled Trial <i>Lorne A. Runge, Robert S. Pinals, Seth H. Lourie, and Russell H. Tomar</i>	1445
Prostaglandin E <sub>1</sub> Treatment of NZB/NZW F <sub>1</sub> Hybrid Mice. II. Prevention of Glomerulonephritis <i>Robert B. Zurier, Ivan Damjanov, Donna M. Sayadoff, and Naomi F. Rothfield</i>	1449
Antibodies to Cytoplasmic Antigens in Lupus Erythematosus: Serologic Marker for Systemic Disease <i>Thomas T. Provost, A. Razzaque Ahmed, Peter J. Maddison, and Morris Reichlin</i>	1457
Clinical Evaluation of D-Penicillamine by Multicentric Double-Blind Comparative Study in Chronic Rheumatoid Arthritis <i>Yuichi Shiokawa, Yoshihiko Horiuchi, Mitsuo Honma, Takamasa Kageyama, Takao Okada, and Takeshi Azuma</i>	1464
A Double-Blind Trial of High Versus Conventional Dosages of Gold Salts for Rheumatoid Arthritis <i>D. E. Furst, S. Levine, R. Srinivasan, A. L. Metzger, R. Bangert, and H. E. Paulus</i>	1473
Lymphocyte Activation in Rheumatoid Synovial Effusion <i>J. Sebök, A. Talerman, and H. W. Wouters</i>	1481
Circulating Immune Complexes and Antinuclear Antibodies in Juvenile Rheumatoid Arthritis <i>R. D. Rossen, E. J. Brewer, D. A. Person, J. W. Templeton, and M. D. Lidsky</i>	1485
Localization of C-Reactive Protein in Synovium of Patients with Rheumatoid Arthritis <i>Jonathan D. Gitlin, Joan I. Gitlin, and David Gitlin</i>	1491

Septic Arthritis of the Glenohumeral Joint: Unique Clinical and Radiographic Features and a Favorable Outcome <i>Robert Master, Michael H. Weisman, Thomas G. Ambuster, Jack Slivka, Donald Resnick, and Thomas G. Goergen</i>	1500
Adjuvant Polyarthritis. III. Evidence in Support of Viral Etiology <i>Yi-Han Chang and William Hoffman</i>	1507
Radioimmunoassay of Serum Myoglobin in Polymyositis and Other Conditions <i>Masahiko Nishikai and Morris Reichlin</i>	1514
Severe Systemic Lupus Erythematosus with Nephritis in a Boy with Deficiency of the Fourth Component of Complement <i>Jane G. Schaller, Bruce G. Gilliland, Hans D. Ochs, John P. Leddy, Lawrence C. Y. Agodoa, and Stephen I. Rosenfeld</i>	1519
Destruction of Joint Homografts: An Experimental Study <i>Isadore G. Yablon, Kenneth D. Brandt, Ronald DeLellis, and David Covall</i>	1526
Adsorption of Polymorphonuclear Leukocyte Lysosomal Enzymes to Monosodium Urate Crystals <i>Mark H. Ginsberg, Franklin Kozin, Donald Chow, James May, and John L. Skosey</i>	1538
Synovectomy and Total Joint Arthroplasty for Recurrent Hemarthroses in the Arthropathic Joint in Hemophilia <i>James T. London, Herman Kattlove, James S. Louie, and Gary L. Forster</i>	1543
Allopurinol Hepatotoxicity: Case Report and Literature Review <i>S. K. Chawla, H. D. Patel, G. R. Parrino, J. Soterakis, P. A. LoPresti, and W. A. D'Angelo</i>	1546
Case Report: Acute Bilateral Symmetrical Pathologic Fractures of the Lateral Tibial Plateaus in a Patient with Gaucher's Disease <i>Frank Seinsheimer III and Henry J. Mankin</i>	1550
Letters	1556
Book Reviews	1571
Books Received	1573
ARA Announcements	1574
Annual Indexes	1575

## **AUTHOR INDEX**

Page numbers in *italics* refer to abstracts. Authors published in the July-August supplement are listed elsewhere.

## A

Abeles M, 825  
Abernethy PJ, 105  
Abou Rizk, 1147  
Abraham GN, 130  
Abrahamsen TG, 772  
Adelstein E, 985  
Agodoa LCY, 1519  
Ahmed AR, 1457  
Akasaka T, 729  
Akizuki M, 105, 131, 693  
Alarcon-Segovia D, 30, 1169, 1288, 1565  
Albini B, 962  
Allison AC, 1396  
Alper CA, 449  
Altman RD, 35, 139  
Ammann AJ, 434  
Amstutz HC, 112  
Andersen RB, 1354  
Anderson K, 130  
Andiman WA, 7  
Andreis M, 969  
Andres G, 962  
Andrews BS, 106  
Andrianakos AA, 1179  
Ansell BM, 176, 204, 245, 341, 363, 414, 526, 536  
Arana RM, 1033  
Arend WP, 1049  
Arkin CR, 91  
Armbruster TG, 1500  
Arnett Jr FC, 106, 120, 797  
Artmann G, 1105, 1240  
Athreya B, 107, 529, 573, 604  
Auclair R, 270, 364, 395  
Ayoub EM, 191  
Azuma T, 1464

## B

Bagby Jr GC, 59  
Baldassare A, 270, 364, 395  
Baldwin JL, 1043  
Baldwin SM, 467  
Baliah T, 962  
Ball GV, 907, 1288  
Balz GP, 189, 531  
Bangert R, 1129, 1473  
Bankhurst AD, 785, 1409  
Barbour BH, 137  
Barnett EV, 1419  
Barracough D, 1413  
Barry PE, 171  
Barton B, 1343  
Bashey RI, 879, 902  
Baud CA, 719  
Baum J, 158, 253, 779, 1029  
Beetham Jr WP, 1142  
Bennett JC, 1031  
Bennett RM, 84, 905  
Benson MD, 107  
Benya PD, 107  
Berg E, 1343  
Berger Jr H, 1198  
Berglof F, 108

Berglof K, 108  
Bernstein B, 108, 135, 184, 212, 241, 279, 287, 313, 343, 351, 356, 357, 402, 1099  
Berzofsky RN, 108, 1320  
Bias WB, 106, 120, 797  
Bloch KJ, 120  
Block SR, 1314  
Bluestein HG, 109  
Bluestone R, 123, 1563  
Bobrove AM, 1326  
Boehm-Truitt MJ, 105, 131  
Bolton WK, 748  
Bombardierc, 1569  
Bondi S, 531  
Bong DA, 905  
Böni A, 1105, 1240  
Boone JE, 257  
Boussina I, 717  
Bowden RE, 123  
Brackertz D, 841  
Brandt KD, 792, 1372, 1526  
Braun WE, 909  
Brawer AD, 109  
Breitenstein MG, 113  
Brentjens J, 962  
Brewer Jr EJ, 231, 513, 1485  
Brighton CT, 125  
Brink SJ, 357  
Brown Jr HE, 1026  
Brunner CM, 748  
Brusman H, 18  
Bruyn CHM, 763  
Buchanan WW, 42  
Budiman-Mak E, 1430  
Budman DR, 110, 123, 124, 829  
Bullough PG, 127  
Bungo MW, 1142  
Burnstein SL, 268, 285, 1429, 1433  
Buse M, 1058  
Bywaters EGL, 145, 256, 271

## C

Calabro JJ, 178, 237, 268, 285, 415, 527, 1428, 1433  
Calin A, 1428  
Cannon R, 499  
Canoso JJ, 1213  
Caritas SN, 111  
Carmichael DJ, 834  
Carpenter CB, 933  
Carr R, 138  
Caruso I, 1438  
Cassidy JT, 181, 208, 224, 260, 315, 327, 351, 392, 441  
Castles JJ, 117  
Castor CW, 110, 859  
Cathcart ES, 107, 109, 134, 140  
Chandler RW, 115  
Chang F, 270  
Chang Y, 1135, 1507  
Charman HP, 110  
Chawla SK, 1546  
Cheatum DE, 761  
Chetlin SM, 111

Chow D, 1538  
Christian CL, 119, 1419  
Chung KS, 1388  
Churchill Jr MA, 111  
Chused TM, 105, 112, 123, 127  
Chylack Jr LT, 217  
Clarke C, 142  
Clemmensen I, 1354  
Cohen A, 1571  
Cohen MJ, 906  
Cohen P, 111  
Condemni JJ, 130  
Conn DL, 133  
Cooke CL, 1421  
Cooper NR, 1304  
Corman L, 985  
Cossio PM, 1033  
Covall D, 1526  
Cracchiolo III A, 112, 1206  
Cronlund M, 120  
Crossley MJ, 1231  
Crowe W, 811  
Cruess RL, 558

## D

D'Angelo WA, 1546  
Dabich L, 351  
Daly V, 131  
Damjanov I, 140, 1449  
Davies GH, 59  
Davis III AE, 449  
Davis P, 1413  
Dayer J, 112  
DeBoer DC, 653  
DeLellis R, 1526  
DeNee PB, 1269  
DeWitt CW, 1192  
Decker JL, 123, 895  
Demers J, 1402  
Denko CW, 113  
Denman SJ, 917  
Dennis MV, 129, 922  
Deshmukh K, 113  
DiBartolomeo AG, 111  
DiSabatino CA, 113  
Diamond HS, 118, 128, 1071  
Diaz-Jouanan E, 1169, 1288  
Dich VQ, 578  
Dito W, 116  
Doft B, 110, 829  
Donde R, 1354  
Donovan WH, 553  
Dorsch CA, 108, 114, 1320  
Dubois EL, 137  
Duffy J, 1179  
Duncan H, 114  
Duncan MW, 1174  
Dwosh IL, 685

## E

Ecker ML, 126  
Ehrlich GE, 23  
Eisman J, 1147  
Eknoyan G, 947  
Ellman H, 1071

Emery H, 363, 385  
Emmanuel G, 1071  
Emmerich TE, 1049  
Engleman EP, 1  
Englund DW, 120  
Epstein WV, 45, 751, 805  
Espinoza LR, 1034, 1569  
Evanson JM, 1231  
Ewald FC, 114

## F

Fallet GH, 717  
Fan PT, 1147  
Fehr K, 1105, 1240  
Feigenbaum SL, 115  
Feinglass EJ, 114  
Fell HB, 1359  
Fessel WJ, 1564  
Field L, 1035  
Fikrig SM, 904  
Finerman GAM, 112  
Fink CW, 183, 378, 578  
Finkelman FD, 118  
Fishman J, 18  
Fleischmajer R, 115, 879, 975, 1440  
Fleming PR, 1198  
Floyd M, 115  
Foad B, 815  
Ford DK, 666, 904, 1226  
Forrester D, 1099  
Forster GL, 1543  
Franklin EC, 124  
Frayha RA, 1148, 1437  
Friedman MH, 1269  
Fries JF, 1032  
Fries JR, 1304  
Froland SS, 772  
Fulton M, 139  
Fumagalli M, 1438  
Furst DE, 1473

## G

Gabay R, 913  
Gabourel JD, 59  
Gabriel D, 1388  
Gall E, 116  
Gallop PM, 125  
Ganuzac, 1560  
Garcia-Morteo O, 1033  
Gatti RA, 123  
Geraci JE, 111  
Gerber DA, 116  
Gerber NL, 124, 1263  
Gershwin ME, 110, 117, 829  
Gerster JC, 717  
Gewurz H, 134  
Giangiacomo J, 395  
Gill Jr JR, 123  
Gillard GC, 834  
Gilliland JN, 117  
Gilliland BG, 1519  
Ginsberg MH, 118, 1538  
Ginsburg WW, 118  
Ginzler E, 118

Gitlin D, 1491  
 Gitlin JD, 1491  
 Gitlin JJ, 1491  
 Glass D, 933  
 Glass DN, 122  
 Glauert AM, 657  
 Glimcher MJ, 125  
 Glovsky MM, 402  
 Goergen TG, 1500  
 Gold R, 1563  
 Goldberg L, 1206  
 Goldlust MB, 937  
 Goldman JA, 997  
 Goldman L, 997  
 Good AE, 100, 1009, 1434, 1562  
 Gordon PA, 1556  
 Gorevic P, 121, 124, 1065  
 Gorman T, 117  
 Gottlieb NL, 1003, 1026  
 Granberry WM, 561, 565  
 Gratwick G, 119  
 Gray RG, 35, 1003  
 Gray RH, 139  
 Grayzel AI, 887  
 Green A, 23  
 Greenbaum J, 736  
 Griffiths MM, 741, 1192  
 Gupta RC, 119  
 Gutowska G, 253, 779  
 Guttadauria M, 1071

## H

Haber E, 120  
 Hadler NM, 1019, 1388  
 Hafeman C, 445  
 Hahn BH, 65  
 Halla JT, 119, 1188  
 Handley CJ, 834  
 Hanissian AS, 192, 341, 497  
 Hanley WS, 1035  
 Hanson V, 108, 135, 155, 184, 212, 279, 287, 343, 357, 361, 402, 548, 1099, 1125  
 Harbeck R, 138, 869  
 Hardin JA, 120, 136  
 Hardin JG, 119, 1188  
 Harris BK, 120, 1561  
 Harris Jr ED, 127, 140, 657  
 Harrity TW, 937  
 Hart M, 985  
 Hashimoto K, 91  
 Hegt VN, 671  
 Henderson E, 1226  
 Henke CJ, 45, 751, 805  
 Henson PM, 118  
 Herbert FA, 1556  
 Herman JH, 192, 922  
 Herzberg M, 702  
 Hess EV, 189, 815, 1032, 1442  
 Hicks RM, 161, 375, 389  
 Hill LL, 947  
 Hill RH, 162, 497, 602  
 Hnatowich DJ, 135, 1334  
 Hochberg MC, 106, 120, 797  
 Hoffman W, 1507  
 Holgate RC, 736

Hollister JR, 544  
 Homlan HR, 131, 693, 1304, 1419  
 Homma M, 1419, 1464  
 Hong R, 419  
 Honig S, 121, 1035, 1065  
 Hoover R, 123  
 Horiuchi Y, 1464  
 Houghton AN, 825  
 Howard Jr J, 578  
 Howell DS, 134  
 Hsu SH, 797  
 Hubscher O, 1033  
 Hunder GG, 111  
 Hungerford DS, 121  
 Hunter T, 685  
 Hurd ER, 122, 969  
 Husby G, 785  
 Hutto JH, 191  
 Hyla JF, 1434  
 Hyler SE, 1033

## I

Ibanez G, 30  
 Ignarro LJ, 73  
 Ingbar ML, 751  
 Irwin J, 125  
 Isaacson AS, 135  
 Isenman M, 130

## J

Jacobs Jr JC, 187, 304, 338, 590, 595  
 Jacobs RC, 1429  
 Jaffe MS, 997  
 Jaffer AM, 134  
 Jawor D, 445  
 Jimenez, SA, 122, 132, 902  
 Joachim CL, 127  
 Jockin H, 962  
 Jonasson O, 499  
 Jordon RE, 119  
 Jubb RW, 1359

## K

Kageyama T, 1464  
 Kamdar A, 137  
 Kammer GM, 122  
 Kang AH, 91, 131, 138  
 Kano K, 962  
 Kantor O, 142  
 Kantor TG, 1381  
 Kaplan D, 118, 1071  
 Kaplan SB, 115  
 Kapusta MA, 1032  
 Kar NC, 132  
 Kark P, 132  
 Kassab H, 124  
 Kassan SS, 105, 112, 123  
 Kassees-Wahid L, 192  
 Katholi RE, 748  
 Kattlove H, 1543  
 Keiser HD, 134, 901  
 Kemple KL, 123

Kent J, 108  
 Keystone EC, 1396  
 Khan MA, 909, 1560  
 Killian PJ, 1080  
 Kimberly RP, 123  
 Kimura H, 1085  
 King KK, 108, 135, 184, 212, 279, 287, 343, 357, 361, 402, 1099  
 Klassen LW, 124, 132  
 Klein RS, 119  
 Klinenberg J, 123, 1032  
 Knotts LL, 65  
 Koehler JP, 332  
 Kohler PF, 869  
 Kojer M, 1558  
 Kolarz G, 1558  
 Kornreich HK, 108, 135, 184, 212, 279, 287, 343, 357, 361, 1099  
 Kourounakis L, 1032  
 Kozin F, 1538, 1559  
 Krakauer RS, 124  
 Kramer R, 1334  
 Krane SM, 112  
 Krey PR, 792  
 Kunkel HG, 18, 1419  
 Kushner I, 811, 909

## L

Lagier R, 717  
 Laitinen O, 1121  
 Lambert PH, 647, 913  
 Lane JM, 125  
 Larter W, 385  
 Laska E, 1381  
 Lauter S, 1034, 1569  
 Lawless OJ, 1080  
 LeRoy EC, 1058  
 Leb DE, 111  
 Leb L, 268  
 Leddy JP, 1519  
 Leirisalo M, 1121  
 Lems PH, 1350  
 Leon SA, 23  
 Lertratanakul Y, 1430  
 Levine S, 1249, 1473  
 Levinson JE, 189, 531, 607  
 Levita M, 702  
 Levitin PM, 748  
 Levo Y, 124  
 Lian JB, 125  
 Lidsky MD, 1179, 1485  
 Lindsley CB, 411  
 Linn JE, 119, 1188  
 Lipinski E, 133  
 Lippiello L, 125  
 Lipsky PE, 118  
 Lipton, M, 125  
 Litwin A, 815  
 Lizzio E, 110, 829  
 Llorente L, 1169  
 LoPresti PA, 1546  
 Lockshin MD, 127, 759  
 London JT, 1543  
 Lorber A, 126

Lotke PA, 126  
 Louie JS, 129, 1543  
 Lourie SH, 917, 1445  
 Lowenstein MB, 1293  
 Lowther DA, 834  
 Lurie HI, 1421

## M

MacDonald NS, 1249  
 Machleder HI, 1129, 1249  
 Mackay IR, 841  
 Maddison PJ, 126, 819, 1457  
 Magilavy DB, 392  
 Mainardi CL, 127, 140  
 Malawista SE, 7, 113, 136  
 Malemud CJ, 709  
 Mankin HJ, 125, 1550  
 Mannik M, 1043  
 Marchesano JM, 285  
 Marcolongo R, 1438  
 Marcus RE, 127  
 Marcus R, 887  
 Marine E, 962  
 Marion T, 130  
 Markenson JA, 127  
 Markowitz M, 369  
 Martel W, 207, 1014, 1217  
 Masi AT, 115, 192, 341, 497, 895  
 Masri AF, 1179  
 Mass MF, 869  
 Massry S, 137  
 Master R, 1500  
 Mathews CHE, 114  
 Maurer K, 132  
 May J, 1538  
 Mayer JW, 901  
 McAdam LP, 989  
 McCarty DJ, 895, 1559  
 McClain B, 1080  
 McCombs C, 851  
 McCutchen JW, 906  
 McDevitt HO, 1037  
 McDonald T, 1343  
 McDuffie FC, 119  
 McIntosh J, 106  
 McIntyre J, 1058  
 McKenna CH, 133  
 McMichael AJ, 1037  
 Medsger Jr, TA, 111  
 Mehta J, 65, 136  
 Meisel AD, 128  
 Meltzer MS, 128  
 Menard HA, 1402  
 Menzel J, 1558  
 Merchant EB, 110, 829  
 Messner R, 1409  
 Metcalf R, 741  
 Metzger AL, 1473  
 Michalski JP, 851  
 Michel B, 653  
 Miescher PA, 647  
 Miller F, 1567  
 Miller III JJ, 243, 269, 308, 332, 729  
 Miller JL, 1033



Miller P, 1326  
Mink J, 1563  
Mitchell GF, 841  
Mitchell NS, 558  
Mitrovic D, 125  
Moore MAS, 59  
Morgan JW, 127  
Morrison DC, 118  
Moskowitz RW, 653  
Moutsopoulos HM, 112, 128  
Murley AHG, 657  
Musgrave DS, 922  
Myttas NJ, 131

## N

Nagase H, 129  
Namey TC, 1058  
Napier MA, 1388  
Nasr FW, 1148  
Nasrallah N, 497  
Natvig JB, 772, 1430  
Nelson JD, 578  
Nies KM, 129  
Nimni ME, 107  
Nishikai M, 1514  
Noall D, 905  
Noble J, 135, 1334  
Nochumson S, 879  
Norby DP, 709  
Norris ML, 1556  
Noyek AM, 736  
Nozoe M, 129  
Nydegger UE, 647, 913  
Nyman KE, 1129

## O

Ochs HD, 1519  
Oei TL, 763  
Ogra PL, 1192  
Ogryzlo MA, 685  
Okada T, 1464  
Olds-Arroyo L, 729  
Olson NO, 1269  
Omenn GS, 549, 322, 473, 484  
Opelz G, 112, 117  
Oppenheim JJ, 128  
Ossi E, 962  
Osterland CK, 1034, 1569  
Overbeek TA, 671  
Osenhandler R, 985

## P, Q

Pachman LM, 445, 467, 499  
Paget SA, 130  
Pahle J, 772  
Palmoski MJ, 1372  
Pardo V, 139  
Parker MD, 130  
Parrino GR, 1346  
Patel HD, 1546  
Patterson CA, 666  
Patzakis MJ, 135  
Paul IL, 131  
Paulus HE, 1129, 1249, 1473

Payne RO, 1037, 1428  
Pearson CM, 132, 989  
Penny R, 106  
Perlish JS, 115, 879, 975, 1440  
Perricone E, 1372  
Perrin LH, 647  
Persellin RH, 137, 1426, 1442  
Person BD, 1179  
Person DA, 1174, 1485  
Petts V, 106  
Petty RE, 181, 224, 260, 315, 327, 351, 392, 441  
Petz LD, 1304  
Phillip JC, 904  
Phillips PE, 110, 130, 459, 584  
Pillarisetty RJ, 434, 1314  
Pinals RS, 1445  
Pitts WH, 989  
Plotz PH, 123  
Podell DN, 130  
Poland M, 23  
Pope C, 1396  
Porta J, 1428  
Poss R, 114  
Postelthwaite AE, 131  
Powell D, 1263  
Powers R, 131, 693, 1304  
Pozderac RV, 1009  
Price GE, 1226  
Pritzker KPH, 736  
Provost TT, 126, 1457  
Puchler H, 134  
Quismorio FP, 137, 1125

## R

Rabin BS, 133  
Radin EL, 105, 131  
Ragsdale C, 315  
Ramirez-Mata M, 30  
Rapp R, 1434, 1562  
Raum D, 933  
Raveche ES, 132  
Reeves JP, 110, 829  
Reeves JRT, 975  
Reginato AJ, 132  
Reichlin M, 126, 133, 819, 1419, 1457, 1514  
Reisberg MA, 947  
Resnick D, 139, 1500  
Reza MJ, 132  
Rich LC, 937  
Rich RR, 1174  
Richfield DF, 997  
Rickaway RH, 947  
Ritchie JC, 110, 859  
Rivero SJ, 1169  
Robinson DR, 112, 1286  
Robinson H, 192, 895  
Robinson HS, 666  
Rodnan GP, 111, 133, 1149  
Rose RM, 105  
Rosen FS, 449  
Rosen PS, 736  
Rosenberg D, 136  
Rosenfeld SI, 1519  
Rosenthal M, 762, 906  
Ross HA, 120  
Ross MR, 7  
Rossen RD, 947, 1485  
Roth SH, 120  
Rothfield NF, 140, 299, 637, 723, 825, 1293, 1449  
Runge LA, 1445  
Russell AA, 471  
Russell IJ, 133  
Rutstein JE, 906

## S

Sacchetti G, 1438  
Sadoff L, 989  
Salmon JW, 604  
Salti IS, 1438  
Santer VB, 834  
Sapolsky AI, 134  
Sasazuki T, 1037  
Sayadoff DM, 140, 723, 1449  
Schacter BZ, 106, 120, 797  
Schaller JG, 153, 165, 227, 277, 312, 363, 385, 398, 443, 470, 498, 537, 598, 1519  
Schapira DV, 1556  
Scheinberg MA, 107  
Scherak O, 1558  
Schlesinger M, 118  
Schloeder FX, 947  
Schmid FR, 134  
Schmitzer TJ, 245  
Schorlemmer HU, 1396  
Schrager MA, 637  
Schroeder ET, 917  
Schultz D, 139  
Schultz JS, 100  
Schumacher Jr HR, 107, 132, 1114  
Schur PH, 122, 500, 933  
Scovern H, 1289  
Scott ME, 110, 859  
Scott RD, 114  
Searles R, 1409  
Sebok J, 1350, 1481  
Segami MI, 1565  
Seinsheimer III F, 1550  
Selenick M, 118  
Sepulveda M, 962  
Sergeant JS, 119, 1145  
Shadle C, 125  
Shapiro AP, 111  
Shapiro B, 23  
Shapiro R, 139  
Sharma JN, 42  
Sharp GC, 985, 1419  
Sharp JT, 1174, 1179  
Sheffer J, 962  
Shiffine M, 117  
Shiohara Y, 1464  
Shirahama T, 107  
Shope RE, 7  
Shortkroff S, 135, 1334  
Shum K, 116  
Silverman SL, 134  
Simkin PA, 1560  
Simon T, 126  
Singer DB, 947  
Singsen BH, 108, 135, 184, 212, 279, 287, 323, 343, 357, 361, 402, 408, 1099  
Skinner M, 107, 125  
Skosey JL, 84, 1538  
Skylv G, 1121  
Sledge CB, 114, 135, 567, 1334  
Slivka J, 1500  
Small P, 869  
Smith CB, 741  
Smolen J, 1558  
Smukler NM, 1114  
Smythe HA, 135, 685  
Snyderman R, 131  
Sokoloff L, 709  
Soter NA, 122, 933  
Soterakis J, 1546  
Spillberg I, 136, 142  
Spohn P, 1409  
Spruance SL, 741, 1192  
Srinivasan R, 1473  
Staley HL, 268, 285, 1429, 1433  
Starkebaum GA, 1049  
Steele FM, 7  
Steere AC, 7, 136  
Stein HB, 666, 685, 1226  
Steinberg AD, 105, 110, 124, 132, 829, 1263  
Steinman CR, 136  
Stenzler SA, 1567  
Stephens RE, 879  
Stern R, 18, 887  
Stevens MB, 108, 114, 1320  
Stiehm ER, 425  
Stillman JS, 171, 510, 933  
Stobie DG, 212, 1125  
Stobo JD, 133  
Storb R, 1043  
Streem A, 1381  
Strober W, 124  
Sturge JC, 1049  
Sturrock RD, 42  
Suarez AF, 134  
Sugarman M, 137, 1125  
Suki, WN, 947  
Sullivan DB, 181, 224, 260, 315, 327, 351, 392  
Suntharalingham K, 904  
Swann DA, 131  
Sweet D, 748  
Syndman DR, 7

## T

Takeuchi A, 137  
Talal N, 434, 1314  
Talerman A, 1350, 1481  
Tan EM, 357, 1419  
Tappeiner G, 119, 142  
Tateishi H, 1085  
Teague P, 1388  
Templeton JW, 1485  
Templin D, 116  
Terasaki PI, 112, 117  
Terman DS, 138

Terry R, 1125  
 Tesar JT, 115  
 Thomas ED, 1043  
 Thomas WH, 114  
 Thompson GR, 1192  
 Thompson Jr HK, 1179  
 Tobias H, 124  
 Tolchin SF, 111  
 Tomar RH, 1445  
 Torrey, SB, 723  
 Tourtellotte C, 604  
 Townes AS, 138  
 Townsend PR, 105  
 Trentham DE, 138  
 Trujeque L, 1409  
 Tsai C, 395  
 Tsang IK, 666  
 Tubergen DG, 441

## U

Urman JD, 825  
 Urowitz MB, 685  
 Utsinger PD, 138, 139

## V

Valenzuela F, 132  
 Van de Putte LBA, 671  
 Vanace PW, 107, 342, 364, 548, 550, 575  
 Van der Korst JK, 763  
 Van Herwaarden CLA, 763  
 Vasey F, 1035, 1569  
 Vasilion P, 962  
 Vater CA, 140  
 Velvart M, 1240  
 Verity MA, 989  
 Vidal AF, 139  
 Voorhees PR, 1198

## W

Wainwright R, 1343  
 Waldmann TA, 124  
 Waldo AL, 1030  
 Walker ER, 1269  
 Walker SE, 139  
 Wallace SL, 895

Waltz DT, 108  
 Wara DW, 434  
 Ward JR, 741  
 Wedgewood RJ, 295  
 Weiner M, 118  
 Weisman MH, 1500  
 Weiss T, 364  
 Weissmann G, 121, 1065  
 Weitzner R, 1430  
 Werb Z, 127, 140  
 Whitehouse MW, 1035  
 Whitney SL, 110, 859  
 Wigley RD, 139  
 Wilber M, 1556  
 Wilcox S, 126  
 Williams GW, 124  
 Williams Jr RC, 785  
 Wilson F, 117  
 Winchester RJ, 887, 907  
 Witzgall D, 114  
 Woessner Jr JF, 129, 134  
 Wolfe F, 1556  
 Woolley DE, 1231  
 Wouters HW, 1350, 1481

## Y

Yablon IG, 1526  
 Yamasaki K, 679  
 Yaron I, 702  
 Yaron M, 702  
 Yelin EH, 45, 751, 805  
 Yonkosky DM, 134, 140  
 Young-Rodechuk M, 1032  
 Yu DTY, 1249  
 Yu T, 895

## Z

Zeiss CR, 134  
 Zeman RK, 1289  
 Ziff M, 118, 122, 679, 1085, 1419  
 Zimmer H, 815  
 Zubler RH, 647, 913  
 Zuckner J, 270, 364, 395  
 Zurier RB, 140, 723, 1449

## **SUBJECT INDEX**

## ARTHRITIS AND RHEUMATISM, VOL. 20, 1977

Page numbers in *italics* indicate papers presented at the Proceedings of the 41st Annual Scientific Session of the American Rheumatism Association, December 9-11, 1976. The Proceedings of the Conference on the Rheumatic Diseases of Childhood (pp 145-636) and Arthritis: A Quarter Century of Research, the Proceedings of the Conference Commemorating the Twenty-Fifth Anniversary of The Arthritis Foundation Fellowship Program (pp S1-S248) are indexed separately.

### A

- ACC, *see* Articular chondrocalcinosis
- Acetylator phenotype, in SLE, 815-819
- Acetylsalicylic acid, in RA, 62  
*see also* Aspirin
- Achilles tendinitis, 1003
- Acid lysosomal protease, 1242  
*see also* Cathepsin D agglutinators
- Acid phosphatase activity, in cutaneous polyarteritis, 1116
- Acidic nuclear antigen, antibodies to, 105
- ACTH, *see* Adenocorticotrophic hormone
- Actinomycin-D, RNA formation and, 707
- Acute monocyclic arthritis, 109
- Acute septic arthritis, gout and, 899  
*see also* Septic arthritis
- Adenocorticosteroids, in lysosomal enzyme discharge, 77
- Adenocorticotrophic hormone, CRP and, 1069
- Adenovirus injection, arthritis and, 138
- Adjuvant-induced arthritis  
  dosing regimen in, 1137-1138  
  immunosuppression and, 1139-1140  
  in rats, 1032  
  suppression of by 6-mercaptopurine, 1135-1140
- Adjuvant polyarthritis, 1507-1512  
*see also* Polyarthritis
- Aerobacter* spp., 779
- Aeromonas hydrophilia*, 1505
- Agammaglobulinemia, polyarthritis and, 892
- Agglutinating antibodies, 1110  
*see also* Cathepsin D agglutinators
- Aggregating IgG, isolation and characterization of, 1390-1391
- Aldosterone hemisuccinate, 81
- Alkaline Congo red method, 1345
- Allograft rejection, antiglobulins in, 958-959
- Allopurinol, 1546
- Alveolar-capillary block, scleroderma and, 1078
- Amacata* (rheumatism), 43
- American Association for the Study and Control of Rheumatic Diseases, 1154
- American Board of Internal Medicine, 1035, 1442
- American Indian, polymyalgia rheumatica in, 1429
- American Rheumatism Association, 56, 805-806, 895, 1149, 1154, 1158, 1457  
  Abstracts of, 105-141  
  Committee on Rheumatology Practice of, 1278-1281
- American rheumatology, history of, 1149-1166  
*see also* Rheumatology
- 6-Aminohexanoic acid, 1380
- Amorphous diamond crystals, chemotactic factor and, 136
- Amyloid protein, in casein-induced amyloidosis, 107
- Amyloidosis  
  amyloid protein in, 107  
  marrow-dependent cell function in, 140  
  secondary, 783
- ANA, *see* Antinuclear antibodies
- Analgesic potency, of antiinflammatory agents, 1381-1386
- ANF, *see* Antinuclear factor
- Ankylosing spondylitis  
  black vs. white patients in, 910-911  
  body hiatus and, 1428-1429  
  clinical features of, 909-911  
  common features with RA, 913  
  complement catabolism in, 913-916  
  genetic susceptibility in, 40  
  HLA-B27 antigen and, 803, 909-911, 1121, 1428  
  immune complexes in, 913-916  
  peripheral joint involvement in, 911  
  renal papillary necrosis and, 917-921  
  skeletal manifestations of, 911  
  with subcutaneous nodules, 1434-1435
- Antibodies  
  anti-DNA, *see* Anti-DNA antibodies  
  antinuclear, *see* Antinuclear antibodies  
  avidity of to DNA in SLE, 23-28  
  cold-reactive, 1049  
  *Crithidia luciliae* in detection of, 811-814  
  DNA, *see* DNA antibodies  
  to ENA in SLE, 114
- Antibody-forming cells, in SLE, 829-834
- Anti-CD Ripley-coated erythrocytes, 1105-1106
- Anticell antibodies, 1051
- Anti-DNA antibodies, in SLE, 1307
- Anti-DNA complexes, DNA binding in, 117
- Antigen-induced arthritis  
  chronicity of, 843  
  histologic characteristics of, 843  
  in mice, 841-849  
  thymus-influenced lymphocytes in, 844
- Antigen molecular weight, DNA binding and, 1322
- Antiglobulins  
  in JRA, 729-735  
  renal localization of, 947-960
- Antiinflammatory agents  
  analgesic potency of, 1381-1386  
  BSA as, 937, 940-942  
  dosages of, 1381-1386  
  in rabbit immune synovitis, 937-945  
  steroidal vs. nonsteroidal, 941-942
- Antimonoocyte antibodies, 1049  
  specificity of, 1054-1055
- Antimyoglobin antiserum, 1514
- Antineuronal activity, in SLE, 109
- Antinuclear antibodies, 1462  
*see also* Anti-DNA antibodies  
  L-asparaginase and, 67  
  complement-fixing activity of, 1033  
  contraceptives and, 21  
  DNA and, 693

- in gold salt therapy, 1432-1433
  - hemagglutination test for, 695-697
  - IgG and, 962
  - immunofluorescence and, 694-697
  - in JRA, 1485-1489
  - LCTAB and, 935
  - in NZB/NZW mice, 725
  - postinjection reactions and, 1189
  - in RA, 653
  - in SLE, 1296-1302, 1320
  - suppression of, 67-68
  - in thoracic duct drainage, 1133
  - Antinuclear factor, in SLE, 817
  - Antiphlogistic regimen, 1151
  - Antismooth muscle antibodies, in scleroderma, 980-982
  - Anti-T-cell antibodies, sex differences in formation of, 132
  - Antithymocyte globulin, T-cell function and, 69
  - Antithyroid antibodies, 21
  - Anti-tissue antibodies, in RA, 1419-1420
  - Antiviral agents, in proteinuria, 124
  - Aplasia, bone marrow, *see* Bone marrow aplasia
  - Aplastic anemia, gold-induced, 1047
  - ARA standard database, 903-904
  - see also* American Rheumatism Association
  - Arm syndrome, rubella vaccination and, 742
  - Arthritics, community care of, 45-56
  - Arthritis
    - acute monocytic, 109
    - adenovirus infection and, 138
    - adjuvant-induced, *see* Adjuvant-induced arthritis
    - amorphous diamond crystals and, 136
    - antigen-induced, *see* Antigen-induced arthritis
    - avian viral, 1275-1276
    - carrageenin-induced, 834-839
    - chronic nondestructive, with polyarthritis, 1114-1119
    - HLA-B27-associated, 120-121
    - hypogammaglobulinemia and, 892-894
    - juvenile rheumatoid, *see* Juvenile rheumatoid arthritis
    - Lyme, *see* Lyme arthritis
    - in papular mucinosis, 989-995
    - patellar whisker and, 1409
    - rheumatoid, *see* Rheumatoid arthritis
    - septic, *see* Septic arthritis
    - yersinia, *see* Yersinia arthritis
    - zymosan-induced, 1396-1400
  - Arthritis and Allied Conditions* (Hollander and McCarty), 1162-1163
  - Arthritis Centers, 2-3
  - Arthritis Clinical Research Center Grants, 1164-1165
  - Arthritis Commission, *see* National Commission on Arthritis and Related Musculoskeletal Diseases
  - Arthritis Coordinating Committee, 5
  - Arthritis Foundation, The, 1, 806, 1149, 1164
  - in community care, 55
  - Manpower Report of, 808-809
  - Arthritis Plan, *see* National Arthritis Plan
  - Arthritis research, 4
  - "Arthritis suspect" category, in diagnostic practice, 1279
  - Arthropathy, rubella vaccination and, 741-746
  - Arthrotropic reovirus, avian synovium infected with, 1269-1276
  - Arthus reaction, IgM rheumatoid factor in, 115-116
  - Articular cartilage
    - in vitro culture of, 107
    - wear of in vitro, 131-132
  - Articular cartilage breakdown, synovial tissue and, 1359-1370
  - Articular chondrocalcinosis, 717-722
  - pathologic findings in, 720-721
  - radiologic and clinical findings in, 719-720
  - AS, *see* Ankylosing spondylitis
  - Aseptic necrosis
    - corticosteroid use and, 827
    - in SLE, 825-828
    - in thalassemia minor, 1147-1148
  - ASMA, *see* Antismooth muscle antibodies
  - Asnase, *see* L-Asparaginase
  - L-Asparaginase
    - antibodies against, 68-69
    - graft-versus-host reactions and, 67
    - in immunologic disorders, 65-70
    - in murine lupus, 69-70
    - spleen cell synthesis and, 66-67
  - Aspirin
    - delayed type hypersensitivity and, 1174-1178
    - hepatotoxicity of, 103
    - vs. 1-isopropyl-4-phenyl-7-methyl-2(1H) quinazoline, 1381
    - pain intensity difference scores with, 1383
    - in RA, 62
    - renal blood flow and, 123
    - in SLE, 123
  - Aspirin-phenacetin mixtures, papillary necrosis and, 919
  - ATG, *see* Antithymocyte globulin; Aurothioglucose
  - Auranofin, as oral chrysotherapeutic agent, 108
  - Aurothioglucose, 1029
  - Autoantibodies, association of, in SLE, 126-127
  - Autologous lymphocytes, in RA, 1249-1251, 1350-1353
  - Avian viral arthritis, 1275-1276
  - Avian synovium
    - arthrotropic reovirus and, 1269-1276
    - normal vs. infected, 1271-1272
  - Axial spondylarthritides, nucleographic studies of, 1058-1063
  - Azathioprine
    - drug toxicity and, 689
    - in early RA, 685-691
    - 6-mercaptopurine and, 1140
    - in RA, 1140
- ## B
- B27, *see* HLA-B27 antigen
  - B27-associated diseases, HLA-A28 antigen and, 106
  - B27+ rheumatic diseases, 1121
  - see also* HLA-B27 antigen
  - Back disease
    - morbid anatomy and radiology of, 1020-1021
    - prevalence of, 1020
  - Back syndrome, as diagnostic category, 1279
  - Bacterial endocarditis, musculoskeletal manifestations of, 111
  - Bacterial endotoxin, platelet and neutrophil sensitivity to, 118
  - Basement membrane immunofluorescence, in RA, 653-655
  - BE, *see* Bacterial endocarditis
  - Bence-Jones proteins, 993
  - Benzamide hydrochloride, 1380
  - BF, *see* Bursal fluid
  - Biopsy needle, intraarticular fragmentation of, 905
  - B-lymphocytes
    - change to Ig-producing plasma cells, 1327
    - corticosteroids and, 1328
    - differentiation of in SLE, 1326-1332
    - spontaneous activation of, 128
  - Bone marrow aplasia, gold-induced, 1043-1047
  - Bone marrow cells, sodium salicylate and, 59
  - Bone-marrow-derived lymphocytes, *see* B-lymphocytes
  - Bone marrow transplantation, in gold-induced marrow aplasia, 1043-1047
  - Bordetella pertussis*, 848
  - Bovine nasal cartilage, neutral protease from, 129
  - Bovine serum albumin
    - dinitrophenylated, 1402



in rabbit immune synovitis, 937  
 rabbit immunization with, 967  
 Brown's syndrome, 1080-1084  
   acquired, 1082  
*Brucella abortus*, agglutination tests for, 1227  
 Bursal fluid  
   characteristics of, 1214-1216  
   in olecranon bursitis, 1213-1215  
 Bursitis  
   defined, 1279  
   olecranon, *see* Olecranon bursitis  
 Butterfly rash, photosensitive, 1459-1463

## C

Clq components, in immune complex binding, 119  
 Clq metabolism, 134  
 C3 complement  
   breakdown of, 647-651  
   hypersynthesis of, 1311  
   <sup>125</sup>I-labeled, 1305  
   in immune complex binding, 119-120  
   in vivo metabolism of in SLE, 1304-1311  
   prednisone therapy and, 1309  
   synthesis rate of, 1310  
 C4 complement, breakdown of, 647-651  
 C4 deficiency, in SLE, 1519-1524  
 Calcific quadriceps tendinitis, 1409-1412  
 Calcium, in rabbit articular chondrocytes, 113  
 Calcium apatite, synovial deposition of, 792-796  
 Calcium pyrophosphate dihydrate crystals, 717, 721  
 California  
   rheumatology manpower in, 805-810  
   University of, 751  
 cAMP, lymphocyte toxicity and, 790  
 CAPA, *see* Cytoplasmic acidic protein antigens  
 Capsulitis, 1279  
*Caraka Samhita, The*, 43  
 γ-Carboxyglutamic acid, in ectopic calcification, 125  
 Carnitine palmityl transferase deficiency, 132-133  
 Carpal tunnel syndrome, 1022  
 Carrageenin  
   intraarticular infection and, 835  
   in proteoglycan synthesis, 834-839  
 Carrageenin-induced arthritis, 834-839  
 Carrageenin-induced paw edema, 1137, 1508  
 Cartilage  
   living synovium and, 1361-1367  
   separation of from synovium, 1367-1369  
 Cartilage matrix proteoglycan synthesis, 834-839  
 Cartilage proteoglycan degradation, 922-930  
   monocyte depletion and, 927  
   T-cell activation and, 922-923, 929  
 Cartilage proteoglycans, modulation of human lymphocyte response by, 129  
 Catcher's crouch syndrome, 741-746  
 Cathepsin D agglutinators  
   defined, 1111  
   incidence and titers of in health and rheumatic patients, 1107-1109  
   in RA, 1240-1247  
 CDA, *see* Cathepsin D agglutinators  
 CDG, *see* Conventional dose group  
 CDLE, *see* Chronic discoid lupus erythematosus  
 Cell-mediated immunity, 922-923  
   in SLE, 818  
 Cellular infiltrates, in scleroderma skin, 115, 975-983  
 Center for Disease Control, 5  
 Central nervous system  
   brain scans and EEG in reference to, 875-876  
   complement studies and, 874-875  
   CSF findings and, 874  
   DNA antibody and, 872-873  
   DNA binding and, 874  
   IgG levels and, 874  
   SLE and, 136-137, 869-877  
 Cervical disvertebral destruction, in RA, 1217-1225  
 Cetylpyridinium chloride, 865  
 cGMP, lymphocyte toxicity and, 790  
 Chalky joint effusion, 792-796  
 Chemotactic factor, cell-derived, 136  
 Chlorambucil  
   in autoimmune disease of mice, 1263-1267  
   cyclophosphamide and, 1263-1267  
 Chloroquine, azathioprine and, 685-691  
 Chondritis, in Wegener's granulomatosis, 1286-1288  
 Chondrocalcinosis  
   patellar whiskers and, 1409  
   tendon calcifications in, 717-722  
 Chondrocyte collagen production, 709-714  
 Chondrocyte metabolism, prostaglandins and, 125  
 Chondrocytes, lapin articular, 709-714  
 Chondroitinase digestion, of medium GAG, 882-884  
 Chondromalacia patellae, as separate entity, 105  
 Chondromatosis, synovial, *see* Synovial chondromatosis  
 Chondrus crispus, 835  
 Chronic discoid lupus erythematosus, 1293-1297  
   antinuclear antibody titers in, 643  
   complement activation pathways in, 637-644  
   DNA antibodies in, 643  
   properdin in, 642  
   serologic studies in, 640-641  
   skin lesions in, 637-638  
   SLE and, 638, 640  
 Chronic polyarthritis, hypogammaglobulinemia of, 887-894  
 Chrysotherapy  
   *see also* Gold salts; Gold sodium thiomalate  
   adverse reactions to, 1413  
   monitoring costs in, 120  
   nonvasomotor postinjection reactions in, 119-120  
   postinjection nonvasomotor reactions during, 1188-1191  
 Cigarette smokers, small airway disease in, 1076-1077  
 Circulating alpha globulin, 107  
 Circulating immune complexes, antinuclear antibodies and, in JRA, 1485-1489  
 Clinical rheumatology, U.S. medical students and, 759-760  
 CMI response, *see* Cell-mediated immune response  
 CNBr-cleavage peptide analysis, 709-714  
 CNS disease, *see* Central nervous system disease  
 CNS-SLE, *see* Central nervous system, in SLE  
 Collagen, arthrogenicity of, 138  
 Collagen phenotype, 107  
 Collagen synthesis, 709-714  
   articular cartilage and, 107  
   in osteogenesis imperfecta, 127  
   by scleroderma fibroblasts, 1440-1441  
 Collagenase  
   immunolocalization studies of, 1233, 1236-1237  
   "latent," 1235  
   localization of at cartilage/pannus junction, 1233-1237  
   in rheumatoid joint, 1231-1238  
   secretion of with plasminogen activator, 140  
 Collodion charcoal, DNA antibodies and, 138  
 Colony stimulating factor, 59  
   salicylate and, 60  
 Columbia University, 1156  
 Community care  
   cost of, 49-50

- counseling and referral agencies in, 54  
 extended patient interviews in, 47-50  
 funding agencies in, 55  
 health care facilities in, 52-53  
 physical therapists in, 51-52  
 physicians and, 50-51  
 planning agencies in, 54-55  
 professional care providers in, 50-52  
 public agencies in, 53-55  
 random telephone survey in, 46-47  
 referrals in, 56
- Community demonstration projects, 3  
 Community Home Health Services, 55  
 Complement activation, in CDLE, 637-644  
 Complement catabolism, in ankylosing spondylitis, 913-916  
 Complement components  
   *see also* C1, C2, C3, etc  
   in AS, 913-916  
   receptors for, 119  
 Complement pathways, in RA, 647-648  
 Complete Freund's adjuvant, in experimental immune arthritis, 1402  
 Concanavallin A, delayed hypersensitivity and, 1177  
 Connective tissue activating peptides, 707, 857-867  
   extraction of, 860  
   fractionation of, 860-861  
 Connective tissue activating peptides III  
   activation of synovial cells by, 863-864  
   characteristics of, 863  
   duration of effect in, 864  
   GAG formation and, 865  
 Connective tissue activation  
   defined, 859  
   isotope incorporation studies and, 861  
   mitogenic activity and, 861  
 Connective tissue disorders, immunoglobulin augmentation in, 133  
 Connective tissue synthesis, by cultured scleroderma fibroblasts, 879-885  
 Convalescent hospitals, in community care, 52-53  
 Conventional dose group, in gold salt dosages, 1475  
 Corticosteroids, B-lymphocytes and, 1328  
 Coulter Counter, 116  
 CPPD crystals, *see* Calcium pyrophosphate dihydrate crystals  
 C-reactive protein  
   levamisole and, 1445  
   localization of in RA, 1491-1497  
   in SLE, 121, 1065-1069  
 Creatine phosphokinase, 1516  
 Cresyl fast violet, 1345  
*Crithidia lucilae*, in DNA-antibody detection, 811-814  
<sup>51</sup>Cr-labeled lymphocytes  
   autologous, 1249  
   reinforced, 1258  
 CRP, *see* C-reactive protein  
 Cryoglobulinemia, necrotizing vasculitis and, 1146  
 Crystal-induced inflammation, footpad swelling and, 113  
 CSF, *see* Colony-stimulating factor  
 CTAP, *see* Connective tissue activating peptide  
 CTD, *see* Connective tissue disorders  
 Cushing's syndrome, digital gangrene and, 1437-1438  
 Cutaneous polyarteritis  
   chronic nondestructive arthritis and, 1114-1119  
   polymorphonuclear neutrophils in, 1118  
 Cutaneous vasculitis, thoracic duct drainage and, 1129-1133  
 Cyclic nucleotides, in lymphocyte autotoxicity, 790  
 Cycloheximide  
   CTAP and, 707  
   plasminogen activator and, 1203  
   poly I:C and, 1507  
 Cyclophosphamide, 685  
   in autoimmune disease of mice, 1263-1267  
   in carrageenin-induced paw edema, 1137  
   chlorambucil and, 1263-1267  
   in SLE, 1267  
   in tubule cell infiltration, 122  
 Cytomegalovirus, in interstitial pneumonia, 1044  
 Cytoplasmic acidic protein antigen, 1420  
 Cytoplasmic antigens, antibodies to, 1457
- ## D
- Dansyl, in plaque assay, 830  
 Data processing, for QSS, 1059  
 Date palm synovitis, 1127  
   puncture injuries and, 1206-1212  
 Degenerative joint disease, 1019  
   articular cartilage in, 1088-1097  
   back disease and, 1020  
   patellar whiskers and, 1411  
   PGE localization in, 786-789  
 DEJ, *see* Dermal-epidermal junction  
 Delayed hypersensitivity  
   aspirin and, 1174-1178  
   intraarticular immunogen and, 1402, 1406-1407  
 Dense granules, lysosomal nature of, 97-98  
 Deoxyribonucleoprotein, 693-700  
   *see also* DNA  
 De Quervain's tenosynovitis, 1003  
 Dermal-epidermal junction, in SLE, 1293-1300  
 Dermal fibroblasts, abnormal collagen synthesis by, 127  
 Diabetes mellitus  
   low back pain and, 1014  
   renal papillary necrosis and, 919  
 Diethyl stilbesterol, 21  
 Digital gangrene, Cushing's syndrome and, 1437-1438  
 Digital mucinous pseudocysts, 997-1001  
   cyst-forming mechanism in, 1000  
   etiology of, 1001  
   surgery for, 999  
   therapy for, 998-999  
 Dinitrophenylated bovine serum albumin, 1402  
   *see also* Bovine serum albumin  
 Dinitrophenylated human serum albumin, 1402-1407  
 Diphenylhydantoin, 59  
 Diplopic screen  
   on Brown's syndrome, 1082  
 Discoid lupus erythematosus, 1457  
 Disseminated immune deposits  
   immunofluorescence microscopy in, 964-965  
   in SLE, 962-968  
 DJD, *See* Degenerative joint disease  
 DLE, *See* Discoid lupus erythematosus  
 DNA (deoxyribonucleic acid)  
   avidity of antibodies to, 23-28  
   binding of to normal skin connective tissue, 117  
   denatured, 27  
   double-stranded, 811-814  
   localizing factor for, 117  
   natural vs. denatured, 25-28  
   single-strand regions in, 108-109  
 DNA antibodies  
   antiviral agents and, 124  
   L-asparaginase and, 67  
   in CDLE, 643  
   extraction of, 138  
   prostaglandin E<sub>1</sub> and, 1450  
 DNA-anti-DNA complexes, renal disease and, 869  
 DNA binding

antigen molecular weight and, 1322  
in SLE, 1300  
DNA formation, stimulation of by platelet factor, 859-867  
DNA synthesis, platelet stimulation of, 110  
DNase digestion, in dsDNA antibody studies, 812  
DNP, *see* Deoxyribonucleoprotein  
DNP-BSA, *see* Dinitrophenylated bovine serum albumin  
Double-stranded DNA antibodies, detection of, 811-814  
D-Penicillamine, *see* entry under P  
Dupuytren's contracture, 1003  
Dysentery, *Shigella* in, 100-103  
Dysprosium 165, in radiation synovectomy, 1334-1341

## E

EACA, *see* Epsilon amino caproic acid  
Ear, chondritis of, 1286-1288  
Ecchymosis, of lower leg, 1009-1013  
ECHO, arthritis and, 14  
Ectopic calcification, 125  
EDTA (edetate)  
in JRA antiglobulin studies, 733-734  
in proteoglycan aggregation, 1380  
EEG, *see* Electroencephalogram  
EHDP, in axial spondylarthritides, 1058  
Elbow arthroplasty, in RA, 114-115  
Elbow epicondylitis, 1003  
Electroencephalogram, in SLE, 875-876  
EMC, *see* Essential mixed cryoglobulinemia  
ENA, *see* Extractable nuclear antigens  
*Endamoeba histolytica*, 101  
Enteric bacteria, antibody levels to, 779-783  
Eosinophilia  
in linear localized scleroderma, 133  
in papular mucinosis, 989-995  
Epidermis, atrophy of in scleroderma, 978  
Epsilon amino caproic acid (EACA) 924, 928-929, 1545  
E-receptor-bearing lymphocytes (ERBL), 1169-1172  
E-rosettes, 1169-1172  
*Erythema chronicum migrans*, 15  
*Erythema infectiosum*, 14  
Erythrocyte sedimentation rate, 1464  
*Escherichia coli*, 102, 779  
Esophagus, metoclopramide and, 30-34  
Essential mixed cryoglobulinemia, liver involvement in, 124  
Estrogen metabolism, in Kleinfelter's syndrome, 20  
Exfoliative dermatitis, 1546  
Experimental immune arthritis, in rabbit, 1402-1407  
Extractable nuclear antigen, 693-700, 906, 985, 1426-1427  
in SLE, 114, 819  
Eye  
anatomy of, 1081  
in Brown's syndrome, 1080-1084

## F

Fab fragments, cathepsin D and, 1242  
Factor B, breakdown of in synovial fluid, 647-651  
FA IgG, *see* IgG, fluorescein-conjugated  
Familial arthropathy, in children, 107  
Familial scleroderma, 37  
published reports on, 38-39  
Familial progressive systemic sclerosis, 35-38  
FANA, *see* Fluorescent antinuclear antibodies  
FDHCR, *see* First-degree household contact relations  
Felt's syndrome, 603  
<sup>165</sup>Dy Ferric hydroxide macroaggregate, in radiation synovectomy, 1335, 1334-1341  
FII (Cohn fraction), 729-734  
Fiber staining, in MCTD, 987

Fibrin-like material, in synovial membranes, 671  
Fibrin plates, preparation of, 1199  
Fibrin slide technique, 672  
Fibrinolysis  
in rheumatoid and nonrheumatoid synovial membranes, 671-677  
in synovial tissue, 673  
Fibrinopeptide A, in SLE serial evaluation, 120  
Fibroblastic dedifferentiation, 713  
Fibroblasts  
chemotactic attraction of, 131  
human synovial, *see* Human synovial fibroblasts  
incubation with <sup>3</sup>H-glucosamine, 879  
uptake of radioactive glucosamine by, 883  
Fibrositis, defined, 1279  
First-degree household contact relations, in SLE, 1293  
Flexor carpi radialis, 1003  
Flexor tendinitis, 1003  
FLM, *see* Fibrin-like material  
Fluorescent antinuclear antibody, 693-700  
Footpad swelling, sympathetic, 113  
*see also* Heel  
Freund's adjuvant, 1402, 1407  
Full-Time Rheumatology Equivalents, in California, 806-810  
Funding agencies, in community care, 55

## G

Gastrointestinal hemorrhage, in MCTD, 1421-1427  
Gaucher's disease, 1550-1554  
*Giardia lamblia*, 100  
Glenohumeral joint, septic arthritis of, 1500-1505  
Glomerular deposits, reactivity of with FA IgG, 951  
Glomerular filtration rate, aspirin and, 123  
Glomerulonephritis  
prostaglandin E<sub>1</sub> and, 1449-1455  
renal localization of antiglobulins in, 947-960  
Glomerulus, sequential cryostat sections from, 954-957  
Glucocorticoids, *see* Glucocorticosteroids  
Glucocorticosteroids  
as antiinflammatory agents, 73-74  
in lysosomal enzyme discharge, 73-81  
neutrophil adherence and, 79  
<sup>3</sup>H-glucosamine incorporation, with scleroderma fibroblasts, 879-885  
Glucose uptake, stimulation of, 859  
β-Glucuronidase, 81, 1539  
Glutamic oxalacetic transaminase, 1516  
Glycosaminoglycan biosynthesis, 838  
Glycosaminoglycan synthesis, 709, 879-885  
platelet stimulation of, 110  
Glycosaminoglycans  
chondroitinase digestion and, 882-884  
CTAP-III and, 865  
electrophoresis and, 882  
fractionation and characterization of, 881-883  
isolation of, 835, 880-881, 1374  
stimulation of by platelet factor, 859-867  
Gold  
*see also* Chrysotherapy  
azathioprine and, 685-691  
circulating pool of, 1186  
therapeutic effect of, 702, 1186  
Gold-induced aplastic anemia, 1047  
Gold-induced thrombocytopenia, 1288-1289  
Gold kinetics, in vivo, 126  
Gold metabolism, 1182  
Gold salt therapy  
aplastic anemia secondary to, 1432-1435  
bone marrow aplasia due to, 1043-1045  
Gold salts

see also Chrysotherapy; Gold; Gold salt therapy  
 conventional dosages in, 1473-1479  
 dosage schedules in, 1179-1187  
 double-blind trial of, 1473-1479  
 gold metabolism and, 1182  
 high dose groups of, 1474  
 D-Penicillamine and, 1413-1417  
 synovial membrane and, 1186  
 Gold sodium thiomalate  
 see also Gold salts  
 myocardial infarction and, 1026-1030  
 postinjection reactions in, 1188  
 Gold thioglucose, 1188-1191  
 Gout  
 acute, see Acute gout  
 classification of arthritis in, 895-900  
 early treatment of, 1150-1153  
 "hygienic measures" for, 1155  
 misplaced, 1151  
 1935 classification of, 1154-1155  
 peccant humours and, 1151-1152  
 primary, see Primary gout  
 retrocedent, 1151  
 retrocessive, 1155  
 rheumatoid factor and, 1147  
 sodium urate monohydrate in, 897  
 tophi in, 899  
 urate crystals in, 897  
 wine drinking and, 1152  
 Gouty arthritis, indoprofen and, 1438-1439  
 Graft-versus-host disease, 1044, 1047  
 L-asparaginase and, 67  
 Granulopoiesis  
 colony-stimulating factor and, 59-63  
 sodium salicylate in, 59-63  
 GST therapy, see Gold salt therapy; Gold sodium thiomalate

## H

Halothane, mitogenic response and, 59  
 Hand flexor tenosynovitis, in RA, 1003-1007  
 Hapten-carrier system, in rabbit experimental immune arthritis, 1402-1406  
 Haptens, as ligands, 830  
 Hashimoto's thyroiditis, 21  
*Haverhillia multiformis*, 14  
 Health care activities, in community care, 48, 52-53  
 Heel, sea urchin spine injury to, 1208  
 Hemalum-eosin reaction, 1346  
 Hemarthrosis  
 in psoriatic arthritis, 1034  
 recurrent, 1543  
 with synovial rupture, 1009-1013  
 Hemochromatosis, arthropathy of, 1430  
 Hemophilia  
 proliferative synovitis in, 127  
 synovectomy and total joint arthroplasty in, 1543-1545  
 Hepatitis B, necrotizing vasculitis and, 1146  
 Hepatotoxicity, allopurinol-induced, 1548  
 Hindpaw edema, carrageenan-induced, 1508  
 Hip cartilage, proteoglycans and aggregate formation in, 1372-1380  
 Hip joint restoration, in JRA, 1099-1104  
 Hip replacement, total, in arthritic children, 135  
 HLA antigens  
 increased frequency of in certain diseases, 1041  
 in lymphocytotoxic antibodies, 933-935  
 in rubella vaccination, 1192-1196  
 as surface glycoproteins, 1037  
 typing of, 1038

HLA-A28, in B27-associated rheumatic diseases, 106  
 HLA-B antigens, typing of, 1038  
 HLA-B27 antigen, 14  
 in ankylosing spondylitis, 120, 909-911, 1428-1429  
 antinuclear antibodies and, 1485  
 in axial spondylarthritides, 1058  
 in B27-negative Reiter's syndrome, 106  
 discovery of, 1159  
 homozygosity from, 797-804  
 in juvenile chronic polyarthritis, 120-121  
 in Reiter's syndrome, 106, 120  
 in rubella vaccination, 1193-1194  
 yersinia arthritis and, 1121-1123  
 HLA-BW 15 antigen, 1054  
 HLA-C antigen, 1038  
 HLA-Cw3 antigen, 1037-1041  
 HLA-D alloantigens, in JRA, 117  
 HLA-Dw3 antigen, in Sjögren's syndrome, 112  
 HLA-Dw4 antigen, in RA, 1037-1041  
 Hodgkin's disease, 855  
 Homan's sign, 1009  
 Homozygosity, disease severity and, 803  
 Housemaid's knee, 1019  
 HPQ, see Hypertrophic osteoarthropathy  
 Human gamma globulin, enhancement of immunoglobulin synthesis  
 by, 679-683  
 Human synovial fibroblasts, hyaluronic acid production by, 702-707  
 Hyaluronic acid  
 aggregate formation and, 1373  
 CTAP-III and, 865-866  
 production of by irradiated human synovial fibroblasts, 702-707  
 proteoglycan fraction digestion by, 1374  
 stimulation of, 859  
 Hydralazine, in SLE, 817  
 Hydroxyapatite crystals, in PSS, 95, 792-796  
 Hypergammaglobulinemia, 993  
 hyperimmunization and, 1394  
 SLE and, 1326  
 Hypertrophic osteoarthropathy, synovial changes in, 139  
 Hyperviscosity syndromes, immunoglobulin abnormalities and, 1388  
 Hypogammaglobulin  
 chronic polyarthritis associated with, 887-894  
 RA and, 893

## I

Ibuprofen, papillary necrosis and, 920  
<sup>125</sup>I-Clq binding activity, in AS, 915  
 IgA (immunoglobulin class), enteric bacteria and, 782  
 IgG (immunoglobulin class)  
 enteric bacteria and, 782  
 fluorescein-conjugated, heat-aggregated, 947, 950-951  
 in RA pathogenesis, 682-683  
 IgG aggregates, 81, 947, 950  
 platelet and neutrophil sensitivity to, 118  
 in RA pathogenesis, 682  
 IgG antibodies, distribution of in SLE, 1314-1318  
 IgG anti-CD Ripley-coated erythrocytes, 1105-1106  
 IgG antigen site, specificity of, 1106  
 IgG fractions, polymerizing, 1390-1393  
 IgG lambda light chain paraprotein, 989, 993  
 IgG, rheumatoid factor, 130-131  
 IgM (immunoglobulin class)  
 enteric bacteria in, 782  
 intracytoplasmic, 1328  
 IgM antibodies, distribution of in SLE, 1314-1318  
 IgM antimonocyte antibodies, in SLE, 1054-1056  
 IgM rheumatoid factor, in Arthus reaction in rat, 115-116  
 Immune complexes

in ankylosing spondylitis, 913-916  
 chronic inflammation and, 973  
 circulating of, 122  
 disseminated, *see* Disseminated immune deposits  
 Immune response, genetic control of, 1317  
 Immune synovitis  
   BSA response in, 940-941  
   measurement of, 938  
   PMNs in, 938-940, 943-944  
   in rabbits, 937-945  
 Immunoabsorption methods, in JRA antiglobulin studies, 730-731  
 Immunofluorescence, demonstration of immunoglobulins by, 653  
 Immunofluorescence micrographs, in PGE localization, 787-789  
 Immunofluorescence microscopy, in SLE immune deposits, 964-965  
 Immunofluorescent antibody test, 780  
 Immunoglobulin, pokeweed-mitogen induced, 1326-1330  
 Immunoglobulin production, in connective tissue disorders, 133  
 Immunoglobulin synthesis  
   enhancement of by human gamma globulin, 679-683  
   heat activation and, 681  
   in SLE, 129  
 Immunologic disorders, L-asparaginase in, 65  
 Immunosuppressive therapy, in pneumocystis carinii and polyarteritis, 1142-1146  
 Incomplete Freund's adjuvant, 1407  
 India, RA in, 42-44  
 Indian medical writings, arthritis in, 42-43  
 Indomethacin, 798  
   papillary necrosis and, 920  
 Indoprofen, in gouty arthritis, 1438-1439  
 Industrial engineers, low back pain and, 1021  
 Industrial rheumatology, 1019-1024  
   aching back in, 1020-1021  
   upper extremity and, 1021-1023  
 Infection frequency, in SLE, 118-119  
 INFH, *see* Ischemic necrosis of femoral head  
 Inflammatory process, immune complexes and lymphokines in, 973  
 Integumental scleroderma, 37  
 Interferon messenger RNA, 1512  
 Interhal medicine, subspecialist in, 1282-1285  
 International Histocompatibility Testing Workshop, 1037  
 International Union of Immunological Societies, 1429  
 Intrabursal hemorrhage, 1215  
 Intrapericardial steroids, in rheumatoid pericardial tamponade, 1289-1290  
 Intravertebral disc herniation, 1222  
 Ischemic necrosis, in femoral head, 121  
*Ixodes ricinus*, 15

## J

Jaundice, *Shigella flexneri* and, 103  
 JCP, *see* Juvenile chronic polyarthritis  
 Joint allotransplantation, metabolic and biomaterial study of, 125  
 Joint fluid, urate fluid in, 896-898  
 Joint homografts, destruction of, 1526-1536  
 JRA, *see* Juvenile rheumatoid arthritis  
 Juvenile chronic polyarthritis, 797, 803  
   HLA-B27 antigens and, 120-121  
 Juvenile rheumatoid arthritis  
   antibody levels to enteric bacteria in, 779-783  
   antiglobulins in, 729-735  
   defined, 13  
   hip joint restoration in, 1099-1104  
   HLA-D and Ia alloantigens in, 117  
   Lyme arthritis and, 8  
   lymphocytes eluted from synovial tissue in, 772-777  
   secondary amyloidosis in, 783  
   sepharose F-11 in study of, 731-734

## K

Keyhole limpet hemocyanin, 1251  
 Kidney immunofluorescence, in mice, 1453  
 Klinefelter's syndrome  
   sex hormone levels in, 20  
   SLE and, 18-21  
 KLH, *see* Keyhole limpet hemocyanin  
 Knee  
   C-reactive proteins in synovium of, 1492-1493  
   date palm thorn injury to, 1209-1210  
   hemarthrosis of, 1009  
   osteonecrosis of, 126  
   radiation synovectomy of, 1334-1341  
   sea urchin spine injury to, 1207  
   synovial rupture of, 1009  
 Knee replacement, polycentric and geometric, 112  
 Knee stiffness, following rubella vaccination, 741-744

## L

Lactate dehydrogenase  
   glucocorticoids and, 79  
   lysosomal enzyme activity and, 1538  
 Lactoferrin, defined, 87  
 Lactoferrin level, in synovial fluid, 84-89  
 Lapine articular chondrocytes, in spinner and monolayer culture, 709-714  
 Lateral tibial plateaus, fractures of, 1550-1554  
 Latex fixation activity, 729, 733-734  
 LCTAB, *see* Lymphocytic antibodies  
 LE cell, antinuclear antibodies and, 1320  
 Lesch-Nyhan syndrome, 1159  
 Leukemia virus antigens, in SLE, 110  
 Leukocyte motility, augmentation of by neutrophil cytoplasmic factor, 137  
 Leukocyte proliferation, salicylate and, 59-63  
 Levamisole  
   future role of, 1447  
   in RA, 1445-1448  
 Liposomes, crystal-enhanced membrane permeability in, 113  
 Liver, spontaneous rupture of, 748-750  
 LM serum  
   IgM antimonocyte antibodies in, 1055  
   studies of, 1054  
 Low back pain  
   *see also* Back disease  
   in industrial rheumatology, 1020  
   radiologically distinctive cause of, 1014-1018  
 Lower leg, ecchymosis of, 1009-1013  
 Lumbago, 1021  
 Lupus nephritis  
   antiviral agents in, 124  
   renal biopsy in, 966-967  
 Lyme arthritis, 7-16  
   age at onset of, 11  
   epidemiology in, 10-12  
   laboratory findings in, 12  
   preceding symptoms in, 9-10  
   serum cryoprecipitates and, 136  
   symptoms in, 13-14  
   traumatic arthritis and, 14  
 Lymphocyte(s)  
   *see also* B cells; B lymphocyte; T cells; T lymphocyte  
   autologous, *see* Autologous lymphocytes  
   <sup>51</sup>Cr-labeled autologous, 1249  
   from JRA synovial tissue, 772-777  
   in RA, 1249-1260  
   synovial cells and, 859  
 Lymphocyte activation, in rheumatoid synovial effusion, 1481-1484



Lymphocyte binding, gold kinetics and, 126  
 Lymphocyte depletion, clinical response to, 1252  
 Lymphocyte factor, in prostaglandin production, 112  
 Lymphocyte function, immunologic disorders and, 65-70  
 Lymphocyte proliferation, in delayed hypersensitivity, 1174-1175  
 Lymphocyte reinfusion, in RA, 1255  
 Lymphocyte rosettes, 1175  
 Lymphocyte toxicity, cyclic nucleotides and, 790  
 Lymphocytotoxic antibodies, 933-935  
   HLA typing and, 934  
 Lymphocytotoxins, SLE, 1049  
 Lymphoid follicles, in RA, 1249  
 Lymphokine-mediated cartilage proteoglycan degradation, 922-930  
 Lysosomal enzyme(s)  
   as inflammation mediators, 74  
   release of, 84  
 Lysosomal enzyme discharge  
   glucocorticosteroid inhibition of, 73-81  
   nonphagocytic, 76  
   time course in, 75  
 Lysosomal enzyme leakage, adrenocorticosteroids and, 77  
 Lysozyme  
   biologic distribution of, 87  
   in monocytes and macrophages, 85  
   source of, 89  
 Lysozyme level, in synovial fluid, 84-89

## M

MAK (methylated albumin-kieselguhr) chromatography, 24  
 $\alpha$ -Mannosidase, 1539  
 Marrow-dependent cell function, in amyloidosis, 140  
 Massachusetts General Hospital, 1156  
 Mast cell, 1035-1036  
 Matrix vesicles, in relapsing polychondritis, 96-97  
 Maximal midexpiratory flow rate, 1071  
 Mayo Clinic, 1156  
 mBSA, *see* Methylated bovine serum albumin  
 MCTD, *see* Mixed connective tissue disease  
 Medical students, clinical rheumatology and, 759-760  
 6-Mercaptopurine  
   in adjuvant-induced arthritis suppression, 1135-1140  
   azathioprine and, 1140  
   in carrageenin-induced paw edema, 1137  
   in nucleic acid biosynthesis, 1138  
 Metalloproteinase Research Group, 1464  
 Methylated bovine serum albumin, 841, 843-848  
 Methylprednisolone sodium succinate, lysosomal enzyme release of, 75-77, 80  
 Metoclopramide  
   action of, 33-34  
   effect on esophagus and esophageal sphincter, 30-34  
   in progressive systemic sclerosis, 30-34  
 Mice  
   *see also* NZB/NZW mice  
   antigen-induced arthritis in, 841-849  
   kidney histology in, 1452  
   zymosan-induced arthritis in, 1396-1400  
 MIF, *see* Migration inhibitory factor  
 Migration inhibitory factor, 930  
   in rheumatoid pericarditis, 969-973  
 Mineralocorticosteroids, in lysosomal enzyme discharge, 73, 80-81  
 Mitogenic activity measurement, CTAP and, 861  
 Mitogens, in lymphocytic culture, 773  
 Mixed connective tissue disease  
   circulating complement-fixing immune complexes in, 130  
   fatal GI hemorrhage in, 1421-1427  
   vs. Sharp syndrome, 905  
   skeletal muscle pathology in, 985-988

Mixed lymphocyte response, 59, 1037  
 MLR, *see* Mixed lymphocyte response  
 MMFR, *see* Maximal midexpiratory flow rate  
 Monocyte-reactive antibodies, in SLE, 1049-1056  
 Monocytic arthritis, 109  
 Monosodium urate crystals, adsorption of PMN leukocyte lysosomal enzymes to, 1538-1542  
 Monosodium urate monohydrate, 1159  
 Monozygotic twin studies, in SLE, 1314-1318  
 Mouse, *see* Mice; NZB/NZW mice  
 Mouse CSF production, salicylate and, 59-63  
 MSU, *see* Monosodium urate crystals  
 Mucopolysaccharide, abnormal, 989  
 Multiple myeloma, 993  
 Munchausen syndrome, 1033  
 Murine lupus, L-asparaginase and, 70  
 Musculoskeletal pain syndromes, as diagnostic category, 1279  
*Mycobacterium tuberculosis*, 786  
 Myocardial infarction, following gold sodium thiomalate induced vasomotor reaction, 1026-1030  
 Myoglobinuria, recurrent, 132-133  
 Myopathy, in papular mucinosis, 989-995

## N

National Arthritis Act (1974), 1-2, 56  
 National Arthritis Data Program, 4  
 National Arthritis Information Service, 4  
 National Arthritis Plan, 1-6  
   budget for, 5  
 National Commission on Arthritis and Related Musculoskeletal Diseases, 1, 5  
 National Institute for Occupational Safety and Health, 1024  
 National Institute of Arthritis, Metabolism, and Digestive Diseases, 214, 1156, 1164-1165  
 National Institutes of Health, 4, 1163-1164  
 NBT, *see* Nitroblue tetrazolium  
 Necrosis, ischemic, in femoral head, 121  
 Necrotizing vasculitis, 1146  
 Nephritis  
   antibodies in, 23  
   SLE and, 1519-1524  
   T-cell function and, 70  
 Nephrosclerosis, 920  
 Neutral metalloprotease activity, from human cartilage, 134  
 Neutral protease agglutinations, in RA, 1240-1247  
 Neutrophils, lysosomal enzyme discharge from, 73-81  
 NHP, *see* Nonhistone protein  
 NIAMDD, *see* National Institute of Arthritis, Metabolism, and Digestive Diseases  
 NIOSH, *see* National Institute for Occupational Safety and Health  
 Nitritoid reaction, gold sodium thiomalate and, 1026-1030  
 Nitroblue tetrazolium, 904  
 Nitroindophenyl, 830  
 NL serum, studies in, 1053  
 Nonhistone protein, 1420  
 Nonmetropolitan community, arthritic care in, 45-56  
 "Not arthritis" category, in rheumatology diagnosis, 1279  
 NPA, *see* Neutral protease agglutinations  
 Nuclear antigens, antibodies to, 693-700  
 Nuclear nonnucleic acid protein, 819  
 Nuclear ribonucleoprotein, antibodies to, 1419  
 Nucleic acid biosynthesis, 6-mercaptopurine and, 1138  
 Nucleographic studies, of axial spondylarthritides, 1058-1063  
 NZB/NZW F<sub>1</sub> mice, therapeutic studies in, 1263-1267  
 NZB/NZW mice  
   altered lymphocyte function in, 65-70  
   B lymphocytes and macrophages in, 128  
   interstitial infiltration of tubule cells in, 122

loss of thymic epithelium materials in, 117  
 prostaglandin treatment, in, 140, 723-727, 1449-1455  
 soluble immune response suppressor in, 124  
 T-cell function in, 69-70

## O

OAF, *see* Osteoclast activating factor  
 Obstructive lung disease  
   clinical and pulmonary function parameters in, 1074  
   scleroderma and, 1077  
 Ocular anatomy, Brown's syndrome and, 1081  
 1-OH estrone, in Klinefelter's syndrome, 20-21  
 Old Lyme, Connecticut, arthritis in, 7-16  
   *see also* Lyme arthritis  
 Olecranon bursitis, idiopathic or traumatic, 1213-1216  
 Oral contraceptives, phytohemagglutinin and, 59  
 Organ culture, articular cartilage in, 1359-1370  
 Organizations, in community programs, 53  
 Osteoarthritis  
   as diagnostic category, 1279  
   erosive, 139  
   loose bodies in, 739-740  
   PGE in synovial tissues of, 785-790  
   synovial fluid and, 84  
 Osteoarthropathy, hypertrophic, *see* Hypertrophic osteoarthropathy  
 Osteochondral grafts, fate of, 1530  
 Osteochondritis dissecans, 739  
 Osteoclast activating factor, 930  
 Osteogenesis imperfecta, 127  
 Osteonecrosis  
   Gaucher's cells and, 1550  
   of knee, 126

## P

Paired cartilage explants, comparability of, 1361  
 Palm thorn synovitis, 1125-1128  
 Palmerston North mice, autoantibodies in, 139-140  
 Pannus-cartilage junction, intracellular collagen fibers at, 657-664  
 Papillary necrosis  
   AS and, 917-921  
   drugs and, 920  
 Papular mucinosis  
   etiology of, 995  
   histopathology of, 989-995  
 PAS reaction, *see* Periodic-acid-Schiff reaction  
 Patellar whiskers, in quadriceps tendinitis, 1409-1412  
 Paws edema, carrageenin-induced, 1137  
 Peccant humours, gout and, 1151-1152  
 D-Penicillamine  
   evaluation of by double-blind comparative study, 1464-1472  
   physician's evaluation of, 1470  
   protein-binding studies and, 1415-1416  
   in RA, 666-670, 1464-1472  
   zinc toxicity with, 1035  
 Pennsylvania, University of, 1156  
 Pericarditis, rheumatoid, *see* Rheumatoid pericarditis  
 Periodic-acid-Schiff reaction, 1344-1346  
 Periosteocytic demineralization, in RA, 114  
 Periostitis, in syphilis, 132  
 Peripheral blood lymphocytes, 679  
 PFC, *see* Plate-forming cells  
 PGC, *see* Proteoglycan(s)  
 PGE<sub>1</sub>, *see* Prostaglandin E<sub>1</sub>  
 PHA, *see* Phytohemagglutinin  
 Phenobarbital, 59  
 Phenylbutazone, 101, 798  
   anuria and, 920  
   in carrageenin-induced paw edema, 1137

  in yersinia arthritis, 1229  
*Phoenix canariensis*, 1127  
*Phoenix dactylifera*, 1127  
 Phosphotungstic acid-hematoxylin, 1344-1345  
 Photosensitive butterfly rash, 1459-1460  
 Physical therapists, in community care program, 51-52  
 Physician(s)  
   in community care programs, 50-51  
   referrals by, 56  
 Phytohemagglutinin  
   in cartilage proteoglycan degradation, 925-926  
   decreased lymphocyte reactivity to, 851-857  
   diethyl stilbesterol and, 21  
   dose-response study of, 853-854  
   kinetic studies in, 854  
   in lymphocyte culture, 773-776  
   lymphocyte responses to, 59  
   in Sjögren's syndrome, 851-857  
 Phytomito-gen-induced proteoglycan degradation, 922-930  
 Picro-Sirius red F3BA reaction, 1344  
 PIR, *see* Postinjection reactions  
 Planning agencies, in community care, 54  
 Plant thorn synovitis, 1125-1128  
 Plaque-forming cells, in SLE, 829-832  
 Plasma renin activity, in progressive systemic sclerosis, 111  
 Plasma viscosity, shear dependence in, 1392-1393  
 Plasmacytosis, of bone marrow, 993  
 Plasminogen activation  
   in collagenase secretion, 140  
   in synovial fluid, 1356-1357  
   kinetics in, 1201-1202  
   levels of, 1202-1203  
 Plasminogen activator, secretion of by rheumatoid and non-rheumatoid synovial cells, 1198-1204  
 Plasminogen activator assays, 1199  
 Platelet factor  
   in connective tissue activation, 859-867  
   in DNA and glycosaminoglycan synthesis, 110  
 Platelet preparations, mitogenic action of on synovial cells, 865-866  
   sensitivity of to IgG aggregates, 118  
 Pleuropericarditis, lymphocyte reinfusion and, 1258  
 PMN, *see* Polymorphonuclear leukocytes  
 Pneumocystis carinii  
   necrotizing vasculitis and, 1146  
   polyarteritis and, 1142-1146  
 Pneumonia, immunodeficiency and, 1142  
 Pokeweed mitogen  
   in B lymphocyte differentiation, 1327-1329  
   in impaired immunoglobulin synthesis, 129  
   in lymphocyte cultures, 772-776  
 Pokeweed-mitogen-induced immunoglobulin secreting cells, in SLE, 118  
 Polyacrylamide gels, electrophoresis in, 819, 1372, 1375  
 Polyarteritis  
   cutaneous, *see* Cutaneous polyarteritis  
   *Pneumocystis carinii* and, 1142-1146  
 Polyarteritis nodosa, 1146  
 Polyarthriti-s  
   adjuvant, *see* Adjuvant polyarthriti-s  
   hypogammaglobulinemia and, 887-894  
   immunoglobulin and, 892  
   nondeforming, 799  
   relapsing, 91-98  
 Polyclonal hyperviscosity syndrome, 1388-1394  
   plasma viscosimetric behavior and, 1391  
   polymerizing IgG factors in, 1393  
 Polyimmune adjuvant arthritis, 1508  
 Polymorphonuclear leukocytes

- adsorption to monosodium urate crystals, 1538-1542  
 in immune synovitis, 937-940  
 in RA, 1396  
 synovial cells and, 859
- Polymorphonuclear lysates, 924-925
- Polymorphonuclear new trophils, in cutaneous polyarthritis, 1118
- Polymyalgia rheumatica, in American Indian, 1429
- Polymyositis, 1426  
 radioimmunoassay of serum myoglobin in, 1514-1518
- Polyriboadenylic acid, in SLE, 1316
- Porphyria cutaneous tarda, 21
- Postinjection reactions, in gold therapy, 1188-1191
- Postrubella vaccine arthropathy, phenotypes or haplotypes in, 1195
- Prednisone, 798  
 in bone marrow aplasia, 1044  
 C3 hyposynthesis and, 1309
- Pregnancy, SLE and, 111
- Primary gout, acute arthritis and, 895-900
- Primary plasmin inhibitor, 1354-1358
- Primer on Rheumatic Diseases*, 1160-1161
- Principles and Practices of Medicine, The* (Osler), 1154
- Probenecid-induced uricosuria, 128
- Professional care providers, in community care, 46, 50-52
- Progressive systemic sclerosis, 1426  
 chalky joint effusion in, 792-796  
 in family, 35-41  
 pathophysiology of, 33-34  
 Raynaud's phenomenon and, 38
- Properdin, in CDLE, 641-642
- Properdin factor B, in rheumatoid arthritis, 647-651
- Propoxyphene HCl, papillary necrosis and, 920
- Prostaglandin(s)  
 chondrocytes and, 125  
 monograph on, 1286  
 for NZB/NZW mice, 140, 723-727, 1449-1455
- Prostaglandin E<sub>1</sub>  
 immune/inflammatory responses and, 140  
 immunohistochemical localization of, in rheumatoid synovial tissue, 785-790
- Proteinuria  
 antiviral agents in, 124  
 in NZB/NZW F<sub>1</sub> mice, 1264
- Proteoglycan(s)  
 and aggregate formation in aged hip cartilage, 1372-1380  
 negatively charged, 129  
<sup>35</sup>S-labeled, 922
- Proteoglycan aggregation  
 failure of in aged hip cartilage, 1372-1380
- Proteoglycan degradation, cartilage, 922-930
- Proteoglycan fractions  
 hyalurine acid digestion of, 1374  
 uronic acid and, 1375, 1378-1379
- Proteoglycan substrate  
 enzyme effect on, 924-925  
 preparation of, 923
- Proteoglycan synthesis, carrageenan injection and, 837-839
- Proteus* spp., 779
- Prunus spinosa*, 1127
- Pseudocysts, digital mucinous, *see* Digital mucinous pseudocysts
- Pseudogout, 1159
- Pseudomonas* spp., 108
- PSS, *see* Progressive systemic sclerosis
- PTAH, *see* Phosphotungstic acid-hematoxylin
- Public agencies, in community care, 53-55
- Public health nurses, in community care programs, 52
- Pulmonary function  
 maximal midexpiratory flow rate and, 1071-1077  
 maximal ventilation in, 1071  
 in scleroderma, 1071-1078
- Puromycin, in cartilage proteoglycan degradation, 928
- Pyrazinamide, in urate secretion, 128
- ## Q
- QPAA (quantitative particle aggregate assay), for rheumatoid factor, 116-117
- QSS (quantitative sacroiliac scintigraphy), 1058-1063  
 data processing and, 1059
- ## R
- Rabbit articular chondrocytes, calcium in, 113
- Rabbit immune synovitis, 937-945
- Rackham Arthritis Research Unit, 1156
- Radiation synovectomy  
<sup>165</sup>Dy ferric hydroxide macroaggregate in, 1334-1341  
 leakage in, 1339-1340
- Radioactive glucosamine, uptake of by fibroblasts, 883
- Radioactive gold, in RA treatment, 702-707  
*see also* Gold salts
- Radioactive yttrium, in RA treatment, 702-707
- Radioimmunoassay, of serum myoglobin and polymyositis, 1514-1518
- Raji lymphocytes, immune complex binding to, 119
- Rat fibroblast interferon, in adjuvant-induced arthritis, 1510
- Rat plasma interferon, 1508  
 adjuvant-induced arthritis and, 1509-1510
- Raynaud's phenomenon, 35  
 PSS and, 38
- Recurrent myoglobinuria, in carnitine palmityl transferase deficiency, 132-133
- Reddy, Calif., arthritis care in, 45-56
- Reflex neurovascular dystrophy, in childhood, 108
- Reiter's syndrome, 14, 797, 803  
 B27-negative, 106  
 following *Shigella flexneri* 2a, 100-103  
 genetic susceptibility in, 40  
 HLA-B27 and, 1121-1123
- Relapsing polychondritis  
 calcifying globules in, 95  
 chondrocyte degeneration in, 93  
 dense granules and vesicles in, 93-94  
 matrix vesicles in, 95-97  
 normal cartilage and, 94-95  
 pathogenesis of, 98  
 symptoms in, 91
- Renal allografts, FA IgG localization in arteries of, 958
- Renal biopsy  
 glomerular antiglobulin deposits in, 952  
 percutaneous, 966-967
- Renal biopsy tissue, resistivity of with fluorescein-conjugated aggregated IgG, 950-951
- Renal blood flow, aspirin and, 123
- Renal disease, DNA-anti-DNA complexes and, 869
- Renal insufficiency, reversible, 137
- Renal morphologic lesions, papillary necrosis and, in AS, 917-921
- Renal prostaglandins, in SLE, 123  
*see also* Prostaglandin(s)
- Renal transplantation, renal localization of antiglobulins following, 947-960
- Residual volume, in pulmonary function, 1077
- Restrictive lung disease  
 clinical and pulmonary parameters in, 1073  
 scleroderma and, 1076
- Rheumatic disease(s)  
 as diagnostic category, 1279  
 early classification of, 1150  
 frequency-related list of, 1281

- immune complex circulation in, 122  
 newly recognized (1949-1976), 1159  
 1935 classification of, 1154-1155  
 stabilization and nomenclature in, 1419-1420
- Rheumatic Disease Clinics, 753-754
- Rheumatic fever, streptococcus and, 1160
- Rheumatoid activity index, 1467
- Rheumatoid arthritis  
*see also* Degenerative joint disease  
 "alphabet of therapy" for, 1156  
 ankylosing spondylitis and, 1434-1435  
 antinuclear antibodies in, 653  
 articular cartilage changes in, 1085-1088  
 auranofin in, 108  
 azathioprine in, 1140  
 bone erosion in, 114  
 Brown's syndrome and, 1080-1084  
 cathepsin D agglutinators in, 1105-1112, 1240-1247  
 cervical discovertebral destruction in, 1217-1225  
 common features with AS, 913  
 complement factor breakdown in, 647-651  
 C-reactive protein in, 1491-1497  
 cytotoxic activity of in rheumatoid synovial cell cultures, 130  
 cytotoxic potential in, 134  
 as diagnostic category, 1279  
 early, 685-691  
 elbow arthropathy in, 114-115  
 fibrolytic activity in, 673-675  
 glomerulonephritis and, 948  
 gold salt therapy in, 702, 1179-1187, 1413, 1473-1479  
 hand flexor tenosynovitis in, 1003-1007  
 HLA-Cw3 and HLA-Dw4 antigens in, 1037-1041  
 in India, 42-44  
 intracellular collagen fibers at pannus-cartilage junction, 657-664  
 levamisole in, 1445-1448  
 low serum sulfhydryl concentration in, 116  
 lymphocyte involvement in, 1249-1260  
 lymphocyte reinfusion in, 1255-1256  
 lysosomal enzymes and, 84  
 multivariate analysis in, 115  
 neutral protease agglutinators in, 1240-1247  
 1935 management of, 1155  
 ocular complications of, 1080-1084  
 outcome prediction in, 115  
 D-Penicillamine in treatment of, 666-670, 1413  
 periosteocytic demineralization in, 114  
 PGE in synovial tissue of, 785-790  
 polymorphonuclear leukocytes in, 1396  
 rheumatoid factor in, 1037  
 seropositive, 913  
 sheath syndromes and, 1083  
 skin basement membrane immunofluorescence in, 653-655  
 in SLE, 1301  
 spine involvement in, 1217-1225  
 synovectomy in, 765-770  
 synovial changes in, 1536  
 synovial fluid in, 647-651  
 synovial inflammation in, 834  
 synovial membrane washings and, 1350-1353  
 T lymphocytes in pathophysiology of, 893  
 tissue injury mediation by immune complexes in, 970  
 whole and T-lymphocyte population response to mitogens in, 127
- Rheumatoid articular cartilage, surface ultrastructure of, 1085-1097
- Rheumatoid factor, 1468  
 discovery of, 1160  
 first demonstration of, 1158  
 immune complexes and, 915  
 immunoglobulin synthesis and, 679-683
- Rheumatoid flexor tenosynovitis, 1003-1006
- Rheumatoid inflammation, of cervical disc, 1217
- Rheumatoid joint, collagenase at sites of cartilage erosion in, 1231-1238
- Rheumatoid lymphocytes, immunoglobulin synthesis of, 679-683
- Rheumatoid pericardial tamponade, intrapericardial steroids in treatment of, 1289-1290
- Rheumatoid pericarditis, macrophage migration inhibitory factor in, 969-973
- Rheumatoid rice bodies, 1343-1348  
 electromicroscopic studies in, 1346-1347  
 fibrin-like material in, 1347  
 immunofluorescence studies in, 1346  
 polarization microscopy in, 1346
- Rheumatoid synovial cell cultures, 130
- Rheumatoid synovial collagenase, 1231-1232
- Rheumatoid synovial effusion, lymphocyte activation in, 1481-1484
- Rheumatoid synovial fluid, primary plasma inhibitor in, 1354-1358  
*see also* Synovial fluid
- Rheumatoid synovial membranes, afibrinolysis in, 671-677
- Rheumatoid vasculitis, necrotizing vasculitis and, 1146
- Rheumatology  
 contributions to (1931-1975), 1160  
 educational program in, 1284  
 growth and development of in U.S., 1149-1166  
 industrial, *see* Industrial rheumatology  
 training in, 1283-1285
- Rheumatology manpower, in California, 805-810
- Rheumatology practice, description of, 1278-1281
- Ribonucleoprotein  
 serum antibody to, 1426  
 soluble, 819
- Ribonucleoprotein antigen, 693-700  
 in SLE, 819-823
- Rice bodies, 1343-1348  
 defined, 1343  
 rheumatoid, *see* Rheumatoid rice bodies
- Rickettsia conorii*, 15
- Rickettsia mooseri*, 15
- Rickettsia prowazekii*, 15
- RNA, antinuclear antibodies to, 693
- RND, *see* Reflex neurovascular dystrophy
- RNP, *see* Ribonucleoprotein
- Rose thorn, inflammation from, 1211
- Rosindale reaction, 1344
- RS, *see* Reiter's syndrome
- Rubella vaccination  
 chronic arthropathy from, 741-746  
 HLA antigens and, 1192-1196
- Rubella virus, saline knee wash and, 742

## S

- SAD, *see* Small airway disease
- Salicylate, *see* Sodium salicylate; *see also* Aspirin,
- Salmonella* spp., 14, 101, 779, 1121
- San Francisco, University of, 756
- Sarcolemmal-basement membrane staining, in MCTD, 987
- Sciatica, 1021
- Scleroderma  
 accelerated intravascular coagulation in, 119  
 cellular infiltrates in, 115  
 familial, 37  
 linear localized, 133  
 pathogenesis of, 975  
 plasma renin activity in, 111  
 pulmonary function in, 1071-1078  
 residual volume in, 1077  
 smokers vs. nonsmokers in, 1076

- Scleroderma fibroblasts  
cellular infiltrates in, 975-983  
collagen synthesis by, 902, 1440-1441  
connective tissue synthesis by, 879-885  
proteins synthesized in, 122
- Sclerosis  
integumental, 35-37  
in low back pain, 1016
- Sea urchin spine, puncture injuries from, 1206-1212
- Sepharose, 729-734
- Septic arthritis  
acute, in gout, 899  
of glenohumeral joint, 1500-1505
- Serum myoglobin, radioimmunoassay of, 1514-1518
- Serum protein sulfhydryl group, histidine inhibitor of oxidation in, 116
- Serum rheumatoid factor, 1468  
*see also* Rheumatoid factor
- SGOT (serum glutamic oxaloacetic transaminase), elevation of, 1469-1471
- Sharp syndrome, vs. mixed connective tissue disease, 905
- Shasta County Public Health Nursing, 53-54
- Sheep red blood cells  
agglutination of, 1158  
delayed hypersensitivity and, 1195  
early rosettes with, 1169-1170
- Shigella flexneri*, 1121  
Reiter's syndrome and, 100
- Shigella* spp., 14, 779
- Sickle trait, papillary necrosis and, 920
- SIRS, *see* Soluble immune response suppressor
- Sjögren's syndrome, 751, 1426
- HLA-Dw3 antigen and, 112  
increased incidence of malignancy in, 123  
lymphoproliferation in, 1394  
in NZB/NZW mice, 1267
- Skeletal muscle, pathology of in mixed connective tissue disease, 985-988
- Skin basement membrane, immunofluorescence of, 693-695
- Skin lesions, in Lyme arthritis, 136
- Sm antigen, purification of, 131
- Small airway disease, 1071  
clinical and pulmonary function parameters in, 1075  
smokers vs. nonsmokers in, 1076-1077
- Smoking, small airway disease and, 1076-1077
- Social Security Administration, in community care, 55
- Sodium dodecyl sulfate, in antibody precipitation, 819-820
- Sodium salicylate  
colony stimulating activity and, 60-61  
in granulopoiesis, 59-63  
toxicity of, 103
- Sodium urate monohydrate, in gout, 897
- Soluble immune response suppressor, in NZB/NZW autoimmune disease, 124
- Soluble nuclear antigens, antibodies to, 693-700
- Spine, rheumatoid involvement of, 1217-1224
- Spinner bottles, collagen synthesis and, 709, 711
- Spleen  
Fab fragments produced by, 1242  
neutral protease agglutinators and, 1240-1247
- Spleen cell synthesis, L-asparaginase and, 66-67
- SS, *see* Sjögren's syndrome
- SSI serum, studies on, 1053
- Statolon, as interferon-inducing agent, 1511
- Streptobacillus moniliformis*, 14
- Streptomyces hyaluronidase, 865
- Subluxation, in cervico-discovertebral destruction, 1217-1221
- Subspecialist  
attributes of, 1282-1285  
training of, 1283-1284
- Subsynovial fibroblasts, viral infection in, 1272-1275
- Sulfamethiazine  
acetylation rate of, 815-818  
in SLE, 816-817
- Sulfated-GAG fractions, 865
- Sulfhydryl concentration, in RA, 116
- Sulfhydryl groups, histidine inhibition of oxidation by, 116
- Synovectomy  
multicenter evaluation of, 765-770  
radiation, *see* Radiation synovectomy
- Synovial biopsy needle, intraarticular fragmentation of, 905
- Synovial cells  
activation of, 859  
collagenase secreted by, 140  
lymphocytes and, 859  
prostaglandin production by, 112  
secretion of plasminogen activator by, 1198-1204
- Synovial changes, in hypertrophic osteoarthropathy, 139
- Synovial chondromatosis, 736-740
- Synovial chondrometaplasia, 736
- Synovial fluid  
activating effect of, 1350-1353  
C3 concentration in, 649-650  
CDA in, 1105  
conflict factor breakdown in, 647-651  
cytotoxic potential in, 134  
hydroxyapatite crystals in, 794-796  
lactoferrin and lysozyme levels in, 84-89  
in osteoarthritis, 84  
phase proteins in, 1357  
plasminogen activation in, 1356-1357  
primary plasmin inhibitor in, 1354-1358
- Synovial membrane, in gold salt therapy, 1186
- Synovial membrane washings, in RA lymphocytes, 1350-1353
- Synovial tissue  
in articular cartilage breakdown, 1359-1370  
immunohistochemical localization of PGE in, 785-790  
living cartilage and, 1367-1368
- Synovitis  
date palm injury and, 1127-1128, 1210  
immune, *see* Immune synovitis  
plant thorn, 1125-1128  
proliferative, 127  
in syphilis, 132
- Synovium  
avian, *see* Avian synovium  
cartilage in contact with, 1361-1369  
dead, 1365  
isolated explants of, 1361  
joint homograft destruction and, 1526-1536
- Syphilis, synovitis and periostitis in, 132
- Systemic lupus erythematosus  
acetylase phenotype in, 815-818  
affinity constants in, 25, 27  
animal model of, 139-140  
antibodies to cytoplasmic antigens in, 1457-1463  
antibody-forming cells in, 829-832, 1049-1056  
anti-DNA antibodies in, 1307-1308, 1320-1324  
antilymphocyte antibodies in, 1331  
antineuronal activity in, 109  
antinuclear antibodies in, 1296-1302, 1320  
arthritis and, 1119  
aseptic necrosis in, 825-828  
aspirin and, 123



autoantibodies in, 819  
 autoantibody/antigen association in, 126-127  
 avidity of antibodies in, 23-28  
 baboon leukemia virus antigens and, 110  
 B-lymphocyte differential in, 1326-1332  
 brain scan and EEG in, 875-876  
 C3 hypersynthesis in, 1310-1311  
 C3 metabolism in, 1304-1311  
 CDLE and, 638, 640  
 cell-mediated immunity in, 818  
 circulating DNA in, 136-137  
 CNS involvement in, 869-877  
 CRP in, 121, 1065-1069  
 cutaneous vasculitis and, 1129-1133  
 cyclophosphamide in, 1267  
 dermal-epidermal junction in, 1293-1300  
 dermatoid arthritis in, 1301  
 vs. discoid lupus erythematosus, 1457  
 disseminated immune deposits in, 962-968  
 DNA antibodies in, 108, 811, 1300  
 DNA binding in, 1316  
 extractable nuclear antigen antibodies in, 114, 819  
 family study of, 1293-1302  
 fibrinopeptide A and, 120  
 first-degree household contact relatives in, 1293-1302  
 genetic factors in, 1317  
 hydralazine in, 817  
 hypergammaglobulinemia in, 819  
 IgM and IgG antibody distribution in, 1314-1318  
 immunoglobulins in sera of, 822-823  
 impaired immunoglobulin synthesis in, 129  
 inactive, 1309  
 infection in, 118, 1067  
 joint destruction in, 1119  
 Klinefelter's syndrome and, 18-21  
 liver rupture in, 748-750  
 lymphocytotoxic activity in, 933, 1049  
 MCTD and, 985, 1426  
 monocyte-reactive antibodies in, 1049-1056  
 monozygotic twin studies in, 1314-1318  
 nephritis and, 1519-1524  
 pokeweed mitogen-induced immunoglobulin and, 118, 1319-1330  
 polyriboadenylic acid in, 1316  
 quantitation of antibodies in, 819-823  
 renal involvement in, 26  
 reversible renal insufficiency in, 137  
 Rheumatic Diseases Clinic patients and, 753-756  
 rheumatic symptoms in, 1296  
 ribonucleoprotein antigen in, 819  
 serum complement values during pregnancy and, 111  
 skin immunofluorescence tests in, 1295-1296  
 Sm antigen purification and, 131  
 soluble nuclear antigens in, 819-823  
 SSi serum in, 1053  
 T-cell function in, 69  
 tests for, 904  
 thoracic duct drainage in, 1129-1134  
 T-lymphocyte subpopulation in, 1169-1172  
 whole and T-lymphocyte population response in, 127  
 Systemic sclerosis, progressive, *see* Progressive systemic sclerosis

## T

TCA, *see* Trichloroacetic acid  
 T-cell function  
   antithymocyte globulin and, 69  
   nephritis and, 70  
 TDD, *see* Thoracic duct drainage

Temporomandibular joint, synovial chondromatosis of, 736-740  
 Tendinitis  
   acute calcific quadriceps, 1409-1412  
   bicipital, 1022  
   calcific, 1022  
   forms of, 1003  
 Tendon calcifications, in chondrocalcinosis, 717-722  
 Tennis elbow, 1019  
 Tenosynovitis  
   hand flexor, 1003-1007  
   at wrist, 1022-1023  
 Thalassemia minor, aseptic necrosis in, 1147-1148  
 Thoracic duct cannulation, unsuccessful, 1252  
 Thoracic duct drainage  
   complications in, 1258  
   with cutaneous vasculitis, 1129-1133  
   humoral immune responses in, 1257  
   in lymphocyte studies, 1249-1250, 1260  
   other effects of, 1257-1258  
   T and B cells in, 1259-1260  
 Thrombocytopenia, gold-induced, 1288-1289  
 Thymic epithelium maturation, in NZB mice, 117  
 Thymidine, uptake of by synovial fluid lymphocytes, 1350-1352  
 Thymocytotoxic antibodies, naturally occurring, 132  
 Thymus-induced lymphocytes, *see* T-lymphocytes  
 Tilorone, as interferon-inducing agent, 1511  
 TLC, *see* Total lung capacity  
 T-lymphocyte subpopulation, in untreated SLE, 1169-1172  
 T-lymphocytes, in RA, 893  
 Tolmetin sodium, 1033  
 Total hip replacement, in arthritic children, 135  
 Total joint arthroplasty, in arthropathic joint in hemophilia, 1543  
 Total lung capacity  
   in restrictive lung disease, 1076  
   in scleroderma, 1071-1073  
 TP-Levanol fast cyanine 5RN reaction, 1345  
 Training guidelines, in rheumatology, 1283-1285  
 Traumatic arthritis, 14, 1125-1128  
 Traveler's diarrhea, 100-103  
*Trichinella spiralis*, 101  
 Trichloroacetic acid, 1414  
   separation technique using, 1416  
 Trichrome stain, for rice bodies, 1344-1345  
 Trinitrophenyl, 830  
 Tubular necrosis, 920  
 Tubulo-interstitial nephritis, 920

## U

Ulnaris tendinitis, 1003  
 Uniform Database for Rheumatic Disease, 1031  
 United States medical students, clinical rheumatology and, 759-760  
 University Rheumatic Disease Clinic, 751-757  
   cost of services in, 752-753  
   SLE patients in, 754-756  
 Urate crystals  
   in gout, 897  
   in joint fluid, 896-899  
 Uric acid  
   discovery of, 1152-1153  
   as xanthine oxidase inhibitors, 135  
 Uricosuria, probenecid-induced, 128  
 Uronic acid  
   distribution of, 137  
   proteoglycans and, 1375  
 Uveitis, circulatory immune complexes in, 106

## V

Vascular staining, in MCTD, 987  
Vasculitis  
  necrotizing, 1146  
  SLE and, 136-137  
Ventilation-perfusion mismatching, in scleroderma, 1078  
Vertebral endplate fractures, in low back pain, 1017  
Vincristine, in thrombocytopenia, 1288-1289  
Viral etiology, evidence in support of, 1507-1512  
Virazole, 1032

## W

Wegener's granulomatosis, ear chondritis in, 1286-1288  
Wrist pain, aseptic necrosis and, 825-828

## X

Xanthine, uric acid and, 135  
Xanthine oxidase inhibitors, 135

## Y

Yale Rheumatology Clinic, 8  
Yersinia arthritis, 803  
  HLA-B27 and, 1121-1123  
  in Pacific Northwest, 1226-1229  
  phenylbutazone in, 1229  
*Yersinia enterocolitica*, 14, 103, 1121, 1226  
  agglutination techniques for, 1227  
Yttrium  
  in RA treatment, 702  
  radioactive, 702-707  
*Yucca aloifolia*, 1127  
Yucca thorn, inflammation from, 1211

## Z

Zinc, toxicity of with penicillamine, 1035  
Zymosan-induced arthritis, 1396-1400

